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ABSTRACT
AN ANAYLSIS OF ACCELERATED ATHEROSCLEROSIS IN THE
HYPERGLYCEMIC HYPERLIPIDEMIC SYRIAN FiB HAMSTER
By
Adele Jeanne Marone
University of New Hampshire, May, 2007
Humans with diabetes mellitus are two to five times more likely to develop
cardiovascular disease and do so at a much younger age than non-diabetics. This study
utilized the Syrian FiB hamster, a model of human atherosclerosis, to: 1. determine
whether one intraperitoneal injection of streptozotocin (STZ) could induce a diabetic-like
hyperglycemic state, 2. compare the development of atherosclerotic lesions between non
treated

(N),

hyperglycemic

(G),

hyperlipidemic

(L)

and

combined

hyperlipidemic/hyperglycemic (L+G) hamsters, and 3. determine whether lesion
development was accelerated due to plasma levels of glucose, triglycerides, total
cholesterol, non-HDL-C, HDL-C, or lipid hydroperoxides, or by the TC/HDL-C or
TG/HDL-C ratio or the expression of MDA or LOX-1 in the vascular wall of the hamster
aortic arch. Plasma, and aortic arch and pancreatic tissue were collected and analyzed at
10 and 20 weeks.
Hamsters receiving one intraperitoneal injection of 40 mg/kg body weight
of STZ had significantly elevated glucose levels compared to non-STZ injected hamsters.
They also exhibited another characteristic of human diabetes, the atherogenic lipid triad
characterized by hypertriglyceridemia, increased small dense LDL, and by week 20

x
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decreased HDL-C levels. The lack of dependence on insulin, and its apparent continued
secretion from the beta cells in the STZ treated hamsters appears to be reflective of
human type II diabetes with the L+G hamster exhibiting the conditions of both insulin
resistance and insulin impairment.

The L+G hamsters also exhibited extremely

accelerated atherosclerosis while the G only hamster exhibited no lesion development.
Hyperglycemia and lipidemia alone independently induced MDA and LOX-1 expression.
The combination of hyperglycemia/hyperlipidemia could potentially increase the
expression of MDA and LOX-1 requiring further investigation to quantitate these levels.
Atherogenesis appeared to be mainly associated with increased TC and non-HDL-C.
While hyperglycemia alone does not appear to induce atherogenesis it may contribute to
the acceleration of atherosclerosis when combined with elevated numbers of small dense
LDL particles, with oxidation a major contributing factor to the formation of such
particles. Our findings suggest that the L+G Syrian FiB hamster is a useful model for
determining the mechanism(s) involved in the development of accelerated atherosclerosis
under the conditions of hyperglycemia.

xi
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INTRODUCTION

Cardiovascular disease (CVD) has been the primary cause of death in the
United States (US) every year except one since 1900. CVD claims more lives in the
US each year than the next five leading causes of death combined. In 2003 the next
five leading causes of death were cancer, chronic lower respiratory diseases,
accidents, diabetes mellitus, and influenza/pneumonia [1, 2].

Nearly 2,600

Americans die of CVD each day which averages approximately 1 death every 34
seconds and in 2001 CVD accounted for 38.5% of all deaths in the US.
According to a Center for Disease Control and National Center for Health
statistics report, if all forms of CVD were eliminated, life expectancy would increase
by almost 7 years. If all forms of cancer were eliminated, life expectancy would
increase by only 3 years. According to the same study, the probability at birth of
eventually dying from CVD is 47%. The statistics for other causes of death are:
cancer - 22%, accidents - 3%, diabetes - 2 % and human immunodeficiency virus
(HIV) - 0.7 % [1, 2]. These statistics demonstrate just how dominant CVD is as a
cause of death in the US.
Based on 2003 population data, the average life expectancy of people bom in
the United States is now 77.5 years [2]. Recent declines in US death rates from CVD,
due to new pharmaceuticals such as the statin drugs, and new surgical techniques, are
largely responsible for the recent improvement in life expectancy. In the US, except
for a relatively small increase in 1993, mortality from heart disease has steadily

1
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declined since 1980 [1]. Even so, CVD is predicted to be the main cause of death not
only in developed countries but worldwide by the year 2020. There are two major
reasons for this. The first is the rapidly increasing prevalence of CVD in developing
countries where there has been a decline in the communicable diseases that were
previously the predominant cause of death. These countries are also beginning to
adopt Western habits such as high fat diets and more sedentary lifestyles, both of
which are major risk factors for CVD. The second and more underlying cause is the
increasing prevalence of two other risk factors, obesity and its associated type II
diabetes, particularly in the United States [3-12].
Atherosclerosis is the primary cause of CVD resulting in many deaths from
heart attack and stroke. Many Americans already have atherosclerotic lesion
formation by their early teens [13] as indicated by the presence of early
atherosclerotic lesions in the coronary arteries of 50% of Americans between 10 and
14 years of age [14].

Atherosclerosis accounts for nearly three-fourths of all deaths

from CVD. Therefore it can be stated that atherosclerosis alone is the leading cause
of age-related morbidity and mortality in the Western world [15].
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CHAPTER I

ATHEROSCLEROTIC LESION DEVELOPMENT

Atherosclerosis is a highly characteristic pathological response in specific
arteries and at specific sites within those arteries. In humans, lesions occur most
often in the abdominal aorta but also occur in the coronary and carotid arteries, in
the arch and descending thoracic aorta, and in arteries in the legs. Lesions form in
arteries that are generally larger than 2 mm, except in diabetics where lesions often
may also form in smaller peripheral arteries.

Areas of turbulent flow or low shear

stress that tend to occur at arterial branch points are more prone to a thickening of
the intima with age. Intimal thickenings in these areas may contain smooth muscle
cells of both the contractile and the synthetic phenotype.

Atherosclerosis is most

likely to develop at these intimal thickenings and they are therefore called lesion
prone areas. While lesion development is a continuous process of varying degrees
it is generally characterized as having three distinct stages: early, intermediate and
advanced.

Early Stage - Fatty Streak Lesions
The early stage lesion is called the fatty streak and as its name implies it is
characterized by the deposition lipid in the arterial intima. These lipids are mainly
cholesterol esters derived from circulating lipoproteins, particularly low density
lipoprotein (LDL).

Some factors that most likely contribute to this lipid

3
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accumulation include (1) an increased plasma concentration of lipoproteins,
especially LDL (2) endothelial dysfunction resulting in an increase in permeability
allowing more of the smaller lipoproteins such as small, dense LDL particles to
enter into the subendothelial space (3) aggregation of these particles due to
interactions with extracellular matrix proteins and (4) entrapment of these particles
due to a change in their physical characteristics such as an increased net negative
charge.
In addition to intra- and extra-cellular lipid accumulation, monocyte
infiltration is also a major characteristic of early stage lesion development. The
adhesion of leukocytes to the endothelium in areas of increased permeability has
been identified as one of the earliest events in atherogenesis [16]. There are three
major groups of cellular adhesion molecules: the selectins, the immunoglobulin
superfamily, and the integrins. All three of these adhesion molecule groups are
involved in the multi-step process of monocyte migration and extravasation across
the endothelium [17, 18]. These adhesion molecules are present on both endothelial
cells (ECs) and leukocytes and each has a very specific role in one of the steps in
this process.
The first step is the margination and rolling of monocytes in response to some
insult or injury to the ECs. Selectins on both monocytes and ECs interact to form a
weak, reversible bond causing the monocytes to slow and roll over the endothelium
[19, 20]. Selectin expression may be induced by the cytokines interleukin-1 (IL-1),
tumor necrosis factor alpha (TNF-a) and bacterial endotoxin.
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The next step is the firm adhesion of monocytes to ECs. The immunoglobulin
superfamily adhesion molecules expressed on ECs responsible for this interaction
are intercellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion
molecule-1 (VCAM-1). The monocytes spread and then firmly adhere via binding
of integrins on their surface, including very late antigen-4 (VLA-4) and lymphocyte
function-associated antigen-1 (LFA-1) to VCAM-1 and ICAM-1 respectively on the
ECs.

ICAM-1 is constitutively expressed on ECs, but its expression can be

increased by exposure to IL-1, interferon gamma (INF-y), TNF-a, and bacterial
endotoxin.

VCAM-1 is upregulated by IL-1, TNF, bacterial endotoxin, and

interleukin 4 (IL-4). While VCAM-1 expression on ECs is lower than ICAM-1
expression, VCAM-1 is the adhesion molecule most implicated in the pathogenesis
of human atherosclerosis [21]. Data also suggests that the engagement of ICAM-1
and VCAM-1 induces intracellular signaling in the ECs which results in the
opening of the endothelial cell-to-cell junctions. Engagement of ICAM-1 and
VCAM-1 also induces reactive oxygen species (ROS) production in ECs [22, 23].
ROS may also interfere with endothelial integrity by oxidizing cysteine residues in
tyrosine phosphatases which then impairs tyrosine phosphatase activity [24], This
also triggers a loss of endothelial cell-to-cell junctions resulting in an increase in EC
permeability at these sites.
In the final steps of the process, the monocytes migrate through these
endothelial junctions into the subendothelial space. In order for this movement to
occur the monocytes have to form new adhesion sites and break old ones. Recently,
junctional adhesion molecules (JAMs) present on both ECs and monocytes have

5
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been shown to function as regulators of this transendothelial migration [25, 26].
platelet-endothelial cell adhesion molecule-1 (PECAM-1) is another junctional
molecule present on both monocytes and ECs that may assist in this movement
[27],
The transendothelial migration of monocytes is also driven by a chemotactic
cytokine concentration gradient.

Chemotactic cytokines, better known as

chemokines, are a large family of small (8 to 14 kDa) extracellular ligands that
interact with 7-transmembrane-spanning G-protein-coupled receptors [28] and are
released by ECs, smooth muscle cells (SMCs) and monocytes already present in the
artery.

Monocyte chemoattractant protein-1 (MCP-1) is the chemokine most

closely associated with atherogenesis. MCP-1 interacts via the C-C chemokine
receptor-2 (CCR2) [29] on the surface of the monocytes.
The third major characteristic of early lesion development is foam cell
formation. Once monocytes enter the subendothelial space they differentiate into
macrophages.

The principle function of macrophages is to engulf particles,

internalize them and destroy them by phagocytosis or endocytosis. Macrophages
internalize excess lipids present in the intima by phagocytosis. As they fill up with
lipid droplets they take on a foamy appearance in histological sections. These lipid
filled macrophages are referred to as foam cells [30].

Interm ediate Stage - Fibro-m uscular Lesions

Foam cells produce growth factors that stimulate SMCs in the media to
proliferate and migrate into the subendothelial intima. The smooth muscle cells, in
addition to engulfing lipid, also produce more proteoglycans and extracellular

6
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matrix

components.

SMC

proliferation

and

extracellular

matrix

(ECM)

accumulation are characteristic of the intermediate or fibro-muscular stage of lesion
development. All of the cells in the arterial wall are able to secrete cytokines that
cause the SMCs in the media to migrate through openings in the internal elastic
lamina and into the intima. These SMCs, along with the matrix molecules they
secrete, form a cap overlying the accumulation of foam cells. It is at this point that
atherosclerotic lesions are said to be in the intermediate or fibro-muscular stage.

Advanced Stage - Complicated Lesions
Eventually, lesions may progress to the advanced or complicated stage.
These lesions are characterized by calcification, visible cholesterol crystals and a
core of dead foam cells and gruel composed largely of cholesteryl esters. Stress
occurs at the shoulder regions on either side of this necrotic core. It is at these
weakened shoulder regions that rupture may occur releasing the highly
thrombogenic gruel and tissue factor from the core. This leads to the formation of
clots or thrombosis that may block the flow of blood within the artery causing the
death of tissues downstream. When this occurs in a coronary artery the death of
heart muscle results in a heart attack. When this occurs in the brain the death of
brain tissue results in a stroke.
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CHAPTER II

ATHEROSCLEROTIC RISK FACTORS

Risk factors related to the development of atherosclerosis were originally
identified through epidemiological studies. The four main risk factors identified to
date are high blood pressure, high total cholesterol, diabetes and smoking [31].
Other risk factors include increased age, physical inactivity, stress, a genetic
component, and other factors such as a lack of fiber or fruit and vegetables in the
diet. It has been estimated that the traditional risk factors such as elevated plasma
cholesterol and diabetes explain about 50% of the genetic component. However, all
of these risk factors combined may account for only two-thirds of the incidence of
atherosclerosis. The possible cause of atherosclerosis unrelated to these risk factors
is the subject of ongoing investigations and many theories have been postulated.
The focus of the research in this thesis is on two risk factors, high cholesterol, or
more precisely LDL cholesterol that has been oxidatively modified, and diabetes
mellitus.

High Cholesterol
The first risk factor for atherosclerosis that was identified was high total
cholesterol. More than 100 genes have been identified related to the synthesis,
regulation, and transport of cholesterol in humans. This is due to the important role
that cholesterol plays in many life sustaining processes such as cellular membrane

8
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physiology, dietary nutrient absorption, reproductive biology via steroid hormones,
stress responses, salt and water balance and calcium metabolism [32]. It therefore is
a striking paradox that this important life sustaining substance has been found to be
responsible for the leading cause of death in the industrialized world.
Elevated total serum cholesterol is unique among all the other risk factors in
its ability to promote the development of lesions in the absence of any of the other
risk factors. Humans with low plasma cholesterol levels have lower levels of
atherosclerotic disease even when other risk factors, such as smoking and
hypertension, are present. It has been demonstrated that a 1% decrease in plasma
total cholesterol concentrations is associated with a 2% decrease in the incidence
of coronary artery disease over a period of 5-8 years [33], Five major statin trials
have provided conclusive evidence of the benefits of reducing cholesterol
concentrations [34-38]. Risk factors, other than increased plasma cholesterol, can
accelerate the atherosclerotic process, but in the absence of dyslipidemia they
contribute little to atherogenesis [39].

In addition, there is no known natural

mammalian animal model exhibiting human-like atherosclerosis in which
atherosclerosis can be induced without altering cholesterol profiles [40]. All of
these facts support the role of cholesterol as a causative factor in the development
of atherosclerosis and therefore, reducing cholesterol with cholesterol lowering
drugs, such as the statins, remains the principle means of reducing atherosclerotic
disease.
The lipoproteins that transport cholesterol also play an important role in
atherosclerosis. Lipoproteins are involved in the task of transporting dietary and

9
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endogenously produced lipids to where they are needed in the body. Elevated LDL,
the major carrier of cholesterol, is a well established risk factor for atherogenesis
[41-43] and of all the lipoproteins its role in the development of atherosclerosis has
received the most attention.
Lipoproteins are spherical particles with lipophilic cores containing varying
amounts of cholesteryl esters and triglycerides.
monolayer of phospholipids.

The core is surrounded by a

Also around the core is one or more long chain

polypeptide(s) called an apoprotein (apo) that enables the transport of core
lipids within the aqueous environment of the blood and tissue. Chylomicrons
transport exogenous dietary lipids. Very low-density lipoprotein (VLDL), LDL,
and high-density lipoprotein (HDL) transport endogenous lipids made mainly by
the liver.
VLDL synthesized by the liver contains high levels of triglyceride fatty
acids. On the surface of VLDL there are two apoproteins, apoB-100 and apoE
enabling the transport of these triglyceride fatty acids either to muscles to be used
for energy or to adipose tissue to be stored for future use. After releasing these
triglyceride fatty acids, the remaining VLDL particle is metabolized to a smaller
cholesterol-rich lipoprotein, LDL, by further removal of triglycerides and a
dissociation of apoE.
LDL is the major carrier of cholesterol to the cells of the body. The core of
LDL is high in cholesterol but also contains fatty acids and some lipid soluble
antioxidants such as a-tocopherol (vitamin E). ApoB-100, the remaining apoprotein

10
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from VLDL, is the only apoprotein on LDL. LDLs principle atherogenic
mechanism is its major role in supplying cholesterol to tissues.
In contrast to VLDL and LDL, HDL is athero-protective [44, 45]. The core
of HDL contains less cholesterol than LDL and much less triglyceride than VLDL.
ApoA-1 is the predominant apoprotein on HDL. HDL’s principle athero-protective
mechanism is its major role in reverse cholesterol transport (RCT), the
transportation of cholesterol from the peripheral tissues back to the liver. In mice
injected with cholesterol, the rate of cholesterol clearance was highly correlated
with the level of HDL providing evidence that RCT contributes greatly towards
decreasing the risk of atherosclerotic lesion formation [46].
Excess cellular cholesterol has harmful effects on the cell membrane.
Some of these effects include a loss of fluidity leading to the dysfunction of integral
membrane proteins and receptors and a disruption of membrane domains causing a
disruption of normal signaling events [32]. The accumulation of cholesterol in
arterial cells can occur via three mechanisms - the endogenous synthesis of
cholesterol by the cells themselves, the uptake of cholesterol-rich lipoproteins such
as LDL via receptors on the cell surface, or by receptor independent insudation.
Multiple pathways have evolved to protect cells against excess cholesterol and the
harmful effects of its accumulation [47].
Cholesterol levels in the cells regulate the production of endogenous
cholesterol by the cell via a feedback mechanism. When the cholesterol levels in
the cytoplasm are low, sterol regulatory element-binding pProtein - 1 (SREBP-1), a
125 kDa transcription factor that is attached to the nuclear envelop and endoplasmic

11
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reticulum, [48, 49] is cleaved and activated. SREBP-1 can then enter the nucleus,
where it binds and activates the transcription of genes that are involved in the
making of endogenous cholesterol. Three-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, the rate limiting enzyme required for the synthesis of
endogenous cholesterol, is one of the genes upregulated. The increased production
of HMG-CoA results in an increased production of endogenous cholesterol by the
cell.

An elevated level of cholesterol in the cell inhibits HMG-CoA reductase

leading to a decreased production of endogenous cholesterol. The down regulation
of endogenous cholesterol synthesis is one way in which the body attempts to
prevent excess cellular cholesterol accumulation.
Cholesterol levels in the cytoplasm are also capable of regulating the
expression of the low density lipoprotein receptor (LDL-R), a cell surface
transmembrane protein, again through the action of SREBP-1 which activates the
transcription of the LDL-R gene.

The role of LDL-R in the regulation of the

plasma cholesterol level has been well established [50, 51]. Upregulation of the
LDL-R leads to the enhanced uptake of LDL from the plasma thereby lowering the
circulating cholesterol levels and increasing cholesterol within the cell [52]. LDL is
recognized by the cells via the attachment of the N-terminal domain of the apoB100 molecule on the LDL surface to the LDL-R. Upon attachment to the receptor
both the LDL and the receptor undergo endocytosis. Once inside the endosomes,
the low pH causes the LDL particle and its receptor to dissociate. The receptor may
then be recycled to the cell membrane where it may bind to additional LDL.
Meanwhile the LDL particle is degraded in the lysosomes. The protein components

12
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undergo hydrolysis to their individual amino acids and the lipid components
undergo hydrolysis to free cholesterol. The hydrolyzed products may then exit the
lysosome and enter the cytoplasm of the cell.
This receptor-mediated uptake of LDL observes saturation kinetics. When
cholesterol levels reach the appropriate level in the cell the cleavage of SREBP-1 is
inhibited. It can no longer enter the nucleus and activate the transcription of the
LDL-R.

As a consequence, LDL-Rs on the cells surface are down-regulated

decreasing the removal of LDL from the plasma by this method and increasing
plasma LDL levels. This receptor mediated process accounts for approximately
88% of the degradation of plasma LDL in mice, 73% in hamsters, and 72% in
rabbits. The amount of plasma LDL degraded by the LDL receptor system can
range from 33 - 66% in humans and averages around 58% in humans consuming
diets relatively low in cholesterol content [53]. The increasing plasma LDL levels
seen in humans as they age is generally due to a decrease in the number or
upregulation of LDL-Rs resulting in a decreased capacity to remove LDL from the
plasma [54, 55]. While the down-regulation of the LDL-R is another way in which
the body attempts to prevent excess cellular cholesterol accumulation it can lead to
an increase in plasma LDL levels and the adverse consequences associated with
such as increase.
When plasma cholesterol levels are elevated, more LDL may enter
through the endothelial cell gap junctions in a non-receptor mediated way. Usually
the arterial EC barrier is selectively permeable.

The glycocalyx, charge, and

compactness of the endothelial basement membrane contribute to its selectivity

13
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toward molecules based on charge and size [56]. The single contiguous layer of
ECs lining the arteries has both tight and gap junctions and the space between the
gap junctions is about 260 Angstroms. The average size of an LDL particle is also
260 Angstroms but ranges anywhere from 200 to 300 Angstroms. Particles less
than 258 Angstroms can easily pass through the gap junctions. A decrease of only
5% in the diameter of LDL can result in a 50% increased rate of LDL uptake [57,
58] through normal gap junctions.
Under normal plasma cholesterol levels passage through endothelial cell
gap junctions usually accounts for approximately 42% of the LDL plasma clearance
in humans with normal LDL-R activity. In those that lack LDL receptor activity it
is responsible for 100% of the LDL clearance that takes place [53, 59-62], Unlike
the receptor dependent process, which occurs primarily in the liver, 60 - 70% of the
receptor-independent transport activity occurs in extrahepatic tissue [53, 59, 60].
This non-receptor mediated uptake of LDL observes linear uptake kinetics, not
saturation kinetics, in response to the plasma LDL concentration [63].

LDL

particles are therefore able to cross the endothelium and enter the intimal space in
direct proportion to their serum concentration.
Elevated LDL probably plays an even bigger role in initiating and
perpetuating atherosclerosis than was initially believed [13] because it is now
known that it is not only the amount of LDL but also particle size and oxidative
state that is important in the development of atherosclerosis. Smaller and/or
oxidized LDL particles have been shown to be more atherogenic than native,
normal sized LDL particles. Since smaller LDL particles are more atherogenic but
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contain less cholesterol than the larger LDL particles measurement of LDL
cholesterol may not be the most accurate indicator of atherogenic potential. A more
accurate measurement may be the determination of the number of LDL particles.
Since there is only one apoB molecule on each LDL particle, the number of
particles can be determined by determining the number of apoB molecules.
However, there is also one apoB molecule on each VLDL particle and every VLDL
particle ends up as an LDL particle. The assumption therefore might be that there
would be a 1:1 ratio between these two particles but the biologic half-life of an LDL
particle is at least nine times longer than that of a VLDL particle [64] so there is
generally a ratio of nine LDL particles to every one VLDL particle in the blood.
Measuring the number of plasma apoB particles, 90% of which is LDL associated,
[65] is therefore a better method in determining LDL atherogenicity than measuring
LDL cholesterol totals.
Endothelial dysfunction also results in an increase in permeability and
allows more of the small, dense LDL particles to enter. There are several theories
on how the endothelial cell barrier may become more permeable. The concept that
is most widely accepted is that EC contraction induced by histamine, a vasoactive
agent, causes the increased extravasation of macromolecules including lipids [56].
More recently it has been determined that histamine may reduce tight-j unction
protein expression causing leaky junctions [66]. In addition, vascular endothelial
growth factor (VEGF) makes the endothelial monolayer leaky [67-69]and focal
leaky areas are often associated with EC division [70].
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The “response to injury” hypothesis originally proposed that endothelial
denudation was the first step in atherosclerosis [71, 72],

However, most

atherosclerotic lesions show no evidence of endothelial denudation so this theory
was later revised to emphasize endothelial dysfunction or “injury” rather than
denudation [73], The response to injury hypothesis de-emphasizes the role of LDL
in initiating atherogenesis and proposes that the initial event in atherosclerosis is an
insult to endothelial and smooth muscles cells [73-75]. One study has demonstrated
that endothelial dysfunction occurs following the ingestion of a high-fat meal but
not

after

a

low

fat

meal

[76]

and

others

have

demonstrated

that

hypercholesterolemia causes focal activation of the endothelium in large and
medium size arteries in humans and animals [77, 78].

Thus, it appears that

increased plasma LDL itself may be responsible for the “injury” or dysfunction of
ECs.
Once inside the intima, LDL particles aggregate. This aggregation of LDL
particles tends to make it more atherogenic as demonstrated in a recent study in
which the prevention of aggregation of LDL prohibited the formation of
atherosclerotic lesions even in the presence of excess LDL [77, 79, 80].
Aggregation can be caused by the interaction between the LDL and the
proteoglycans in the intima. Proteoglycans are macromolecules composed of a core
protein and complex, long side-chain carbohydrates called glucosaminoglycans
(GAGs). Aggregation of LDL has been shown to result primarily from direct ionic
interactions between positively charged residues on the apoB molecule and
negatively charges moieties of the proteoglycans.

The interaction can also be
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indirect, via bridging molecules such as lipoprotein lipase (LPL) [81] secreted by
macrophages [82, 83].
effect.

Depending on its location LPL may have an opposing

When present on the endothelium it acts on circulating triglyceride

lipoproteins in an anti-atherogenic manner but when present in the intima it
enhances LDL and proteoglycan binding thereby increasing the proatherogenic
effects associated with LDL aggregation [84].
The retained LDL can further induce its own aggregation [85].
Aggregation can also be induced by the enzymatic lipolysis of LDL by secretory
phospholipase A2 [86] or by secretory sphingomyelinase (sSMASE) [87, 88], In
a study using mice expressing LDL defective in proteoglycan binding as
compared to wild-type mice, Boren et al [80] demonstrated that the mice
expressing

the

LDL

defective

in

proteglycan

atherosclerosis than the wild-type mice.

binding

developed

less

This supports the importance of

proteoglycan binding as an early event in atherosclerosis.
There is some evidence that increased permeability at the sites of lesions
does not fully explain the extent of lipid accumulation.

The accumulation of

lipids may also occur as a defect in lipid egress [89-92], Once the LDL particles
aggregate they may no longer exit the cell but become entrapped within the
cytoplasm.

Entrapment of LDL particles due to a change in their physical

characteristics as a cause for atherogenesis is the foundation of two somewhat
similar hypotheses o f atherogenesis. One of these is the “response to retention”
hypothesis and the other is the “oxidized LDL” hypothesis.

The response to

retention hypothesis proposes that the initiating event in atherosclerosis is the
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retention and accumulation of LDL and other lipoproteins [93]. The basis of the
oxidized LDL hypothesis is that the LDL retained is oxidized and that it is the
oxidation that may be the initiating event in atherosclerosis.

Oxidized LDL
While elevated levels of LDL were initially associated with the risk for
atherosclerosis, in vitro studies suggested that LDL itself was not atherogenic [51,
94], In fact, incubation of LDL with normal macrophages possessing normal
LDLRs did not support foam cell formation. The idea that the modification of
LDL increases its atherogenic potential is just a little over 20 years old [95-97].
Brown and Goldstein first observed that chemical modification of LDL, in the
form of acetylation, led to foam cell formation when incubated with macrophages.
In 1979, Hessler and colleagues [98] demonstrated that LDL that had been
oxidized caused injury to cells in vitro and speculated that oxidized LDL (oxLDL)
might be important in atherogenesis.

It was speculated, however, that the

presence of anti-oxidants would prevent the oxidation of LDL in vivo.
But more recently the occurrence of LDL oxidation in vivo has been
supported by several pieces of evidence.

Oxidized apo B-100 epitopes and

increased levels of lipid peroxidation products have been detected in the LDL
extracted from both rabbit and human atherosclerotic lesions [99]. Immunohistochemical staining of atherosclerotic lesions with specific monoclonal
antibodies also has demonstrated the presence of oxLDL [100].

In addition,

circulating anti-oxLDL antibodies have been found in human plasma and the
levels of this anti-oxLDL correlate with the progression of atherosclerotic lesions
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[101].

Also there is epidemiological evidence, including case-control and

prospective cohort studies, indicating that low antioxidant consumption is
associated with an increased risk of CVD [102-104]. Finally, studies in different
animal models of atherosclerosis strongly suggest that progression of lesions can
be delayed by intervention with several different antioxidants such as probucol,
vitamin E, diphenylphenylene-diamine (DPPD), and butylated hydroxytoluene
(BHT) [105-120]. In order to demonstrate that lesion reduction was due to the
antioxidant activity of probucol and not its cholesterol lowering properties Carew
et al., [121] treated one group of rabbits with probucol and another with
lovastatin, an HMG-CoA reductase inhibitor that lowers cholesterol without
antioxidant protection.

Both groups had lower total cholesterol but only the

probucol group had a reduction in the extent of atherosclerosis thereby
demonstrating that the effect was due to probucol’s antioxidant not its lipid
lowering activity.
While LDL may undergo other modifications, including chemical,
glycation, hydrolysis, and immune complex formation, oxidation is the most
likely in-vivo modification of LDL in the arterial wall [94, 122-124] and the one
most closely associated with atherosclerosis [125].

However, there is still no

confirmation that there is an absolute requirement for LDL oxidation to initiate
atherogenesis.
Oxidation of LDL is caused by a wide variety of ROS. ROS are largely
produced by the arterial cells themselves as either by-products of their normal role
or as a specific response to inflammatory stimuli. All three cell types involved in
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atherosclerotic lesion development, ECs, SMCs and macrophages, are capable of
contributing to the oxidation of LDL.
The term free radical has been equated with ROS, or oxidants, but by
definition a radical is a molecule possessing an unpaired electron. However, with
the exception of the hydroxyl radical most other free radicals are not strong
oxidants. ROS such as hydrogen peroxide, superoxide, and the hydroxyl radical
are products of normal oxygen metabolism. They are generated as a result of
energy production from the mitochondria via the electron transport chain and as
part of the respiratory burst utilized by white blood cells to destroy invading
microorganisms. LDL may be modified by any enzyme system that can generate
free radicals which includes myeloperoxidase, lipoxygenase, phospholipase and
sphingomyelinase. All of these enzymes are present within arterial wall cells.
The oxidation hypothesis emphasizes the significance of the oxidative
modification of LDL and the subsequent responses [126]. Oxidation of LDL occurs
primarily in the intimal microdomains where, as previously discussed, it may be
bound to proteoglycans and aggregated [127], Oxidation of LDL is influenced by
extrinsic local factors such as pH, transition metal availability, the presence of
specific enzyme systems, and local antioxidant concentrations. For example, an
acidic environment will promote LDL oxidation by certain enzymes and may also
effect the interactions of LDL with arterial wall components. Internal factors such
as the antioxidant content and fatty acid composition of LDL also affect its
susceptibility to oxidation.
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All the particles in LDL are susceptible to oxidative modification. ROS
react with all classes of biological molecules but the polyunsaturated fatty acids
(PUFAs) are particularly susceptible because of their double bonds.

A high

proportion of PUFAs in the LDL particle make it more susceptible to oxidation
whereas a high proportion of monounsaturated fatty acids (MUFAs) protects
against oxidation [128].

The molar ratio of PUFA to antioxidant in the LDL

particle is also important in determining its susceptibility to oxidation with a higher
ratio increasing susceptibility [129, 130], In addition, small dense LDL particles
are more susceptible to oxidation than large less dense particles [131, 132] due to
their lower levels of alpha-tocopherol and ubiquinol-10, two important antioxidants.
Known as lipid peroxidation, the oxidation of PUFAs in LDL is particularly
damaging because it proceeds as a self-perpetuating chain-reaction.

In lipid

peroxidation a free radical, such as the hydroxyl radical (OH), abstracts a hydrogen
atom from a PUFA double bond.

An unstable carbon centered lipid radical is

produced (L-). Because of its instability it undergoes a molecular rearrangement
resulting in a more stable conjugated diene. But even the more stable conjugated
diene reacts very quickly with molecular oxygen forming a lipid peroxyl radical
(LOO ).

The lipid peroxyl radical further propagates the peroxidation chain

reaction by abstracting a hydrogen atom from a nearby PUFA. The resulting lipid
hydroperoxide (LOOH) can easily decompose to form a lipid alkoxyl radical (LO-).
These decomposed lipid hydroperoxides can undergo beta-scission reactions
forming reactive aldehyde compounds such as malondialdehyde (MDA) and 4hydroxynonenal (4-HNE). Since oxidants themselves are very short lived most
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studies focus on the products of oxidation reactions, such as MDA and 4-HNE,
which readily combine with functional groups on proteins, lipoproteins, and DNA
potentially altering their behavior. Alpha tocopherol can break the chain reaction
by forming a tocopherol radical. While this is still a radical species it is one that
has very low reactivity. The tocopherol radical can be reduced by co-antioxidants
such as ascorbate (vitamin C) and be exported out of the lipoprotein particle into the
aqueous phase thus leading to chain termination as opposed to chain propagation.
HDL also contains an enzyme called paroxonase, which has been shown to protect
LDL from oxidation and prevent accumulation of lipid peroxidation products on
LDL.

This antioxidant effect of HDL is another method, along with its role in

RCT, by which it is athero-protective.
Once produced, reactive aldehydes can diffuse and cause cytotoxic and
mutagenic damage [133, 134], They also readily bind to lysine groups in the apoB100 protein molecule, forming Schiff bases and altering the surface charge of LDL.
Oxidative

modification

of proteins

may result

in

cross-linking,

peptide

fragmentation, or in the conversion of one amino acid to another.

These

modifications may alter the secondary and tertiary structure of the protein and in
doing so may subject previously unexposed regions to further oxidation.
As much as 1% of the oxygen consumed by the average human may
oxidatively modify proteins. In an elderly person 30 - 50% of their total cellular
protein may be oxidatively modified [135] because there is less protection against
oxidative modification in old cells and tissues than in young ones. LDL lipid
peroxidation does not represent the only manifestation of oxidative stress that may

22

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

be important in atherosclerosis. Recent research indicates that other oxidative
events may be present and could play a role in atherogenesis including the
nonenzymatic oxidation of the phospholipids in LDL particularly those containing
arachidonic acid at the sn-2 position [136].

Comprehensive reviews of the

oxidative modification hypothesis of atherosclerosis have been published [137139],
LDL that is oxidized is not a single, well-defined entity. Its structural and
physical properties vary according to the degree of oxidation [140]. The degree of
oxidation is affected by the type of oxidant and the length of exposure to the
oxidizing environment.

Native LDL itself is heterogeneous and therefore a

homogeneous product from oxidation would be impossible, particularly since there
are many different components of the LDL particle such as cholesterol,
phospholipids, cholesteryl esters, triglycerides and the protein portion that all may
be oxidized to varying degrees [141]. The degree of modification can range from
“minimal” (mmLDL), where the LDL particle is still recognized by the native LDL
receptors [142], to extensively oxidized LDL (oxLDL), where the LDL particle is
no longer recognized by the LDL receptor.
The biological effects of oxLDL also vary according to its degree of
oxidation and the component that is oxidized.

Evidence suggests that most of the

atherogenic effects of oxLDL are derived from oxidized lipid components. The
induction of adhesion molecules at the endothelial cell surface, such as VCAM-1
and ICAM-1 for the adhesion of monocytes, is affected by oxidized fatty acids and
oxidized phospholipids, such as lysophosphatidylcholine (LPC).

LPC is also
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chemotactic to both monocytes and T-cells by inducing MCP-1. All three stages of
monocyte binding: tethering via selectins, activation, and attachment are effected.
OxLDL is also chemostatic for tissue macrophages. This could contribute to the
trapping of macrophages once they have entered the subendothelial space. Oxidized
fatty acids also increase the proliferation of arterial SMCs and highly oxidized LDL
can inhibit endothelial cell migration which may hinder the repair of ulcerated
plaques in advanced lesions.

OxLDL has also been shown to be cytotoxic to

macrophages and endothelial cells. This may contribute to an amplification of the
inflammatory process and the formation of the necrotic core found in advanced
lesions. Oxidized LDL may also directly alter the vasomotor properties of coronary
arteries by inhibiting the ability of endothelial cells to release endothelium-derived
relaxing factor or nitric oxide (NO). In addition to these biological effects, oxidized
lipids and oxidants also appear to activate matrix metalloproteinases (MMPs) which
might play a role in advanced plaque instability and rupture. They also promote
pro-coagulatory responses from both the endothelium and platelets and have many
other atherogenic effects.

Diabetes mellitus
In contrast to the decrease in overall death rates for CVD, death rates for
diabetes have been gradually increasing since 1986. Diabetes was the sixth leading
cause of death in 2000, however, this is probably under reported as only 35 - 40%
of diabetics have the disease listed anywhere on their death certificate and only 10 15% have it listed as an underlying cause of death. Diabetics are also two to five
times more likely to develop CVD than non-diabetics [143, 144]. In people with
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diabetes, risk factors for CVD include elevated fasting plasma glucose, elevated
blood pressure, elevated cholesterol and triglycerides and obesity.

These partly

explain the 60- 70% of deaths caused by CVD in people with diabetes [7],
Diabetes mellitus is a syndrome initially characterized by a loss of glucose
homeostasis. Normally glucose levels are elevated in the blood following a meal.
In response, insulin, the hormone that allows glucose to enter the cells of the body,
is secreted from the beta cells of the pancreas. Type I diabetics have a complete
lack of insulin production due to the destruction of their beta cells. Type I diabetes
exists in two forms; immune mediated or an idiopathic form. Regardless of the
cause, the beta cells of the pancreas are destroyed and little or no insulin is
produced. At diagnosis, 50% of type I diabetics have antibodies against insulin
and/or antibodies against islet cells of the pancreas. It is estimated that 5 - 10% of
Americans who are diagnosed with diabetes have type I diabetes. This type of
diabetes generally has a rapid onset that occurs most frequently in juveniles and
therefore type I diabetes was at one time referred to as juvenile onset diabetes. It
also requires the administration of insulin and therefore has been referred to as
insulin dependant diabetes. However, these two terms may no longer exclusively
describe type I diabetes and therefore are no longer used.
The majority of diabetics, 90 - 95%, have type II diabetes mellitus. Type II
diabetics are either insulin resistant (IR) or insulin deficient, depending on the stage
and progression of the disease. The appearance of overt type II diabetes is typically
preceded by a pre-diabetic period in which the patient displays insulin resistance
and hyperinsulinemia but relative normoglycemia. In insulin resistance the cells of
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the peripheral tissues, such as skeletal muscle, are not as sensitive to insulin and
therefore require more insulin to take up glucose. In response to the cells being less
sensitive to insulin the beta cells compensate by increasing insulin production
leading to hyperinsulinemia.

However, eventually the beta cells cannot secrete

enough insulin to overcome insulin resistance. During this time the insulin levels
remain elevated, often above normal levels, but not high enough to cause the
peripheral cells to take up an adequate amount of glucose.

Eventually the body

cannot maintain these high levels of insulin production. The beta cells produce
decreased insulin and hypoinsulinemia and hyperglycemia, the hallmarks of
diabetes, develop.
From 1980 through 2004, the number of Americans with diagnosed diabetes
more than double from 5.8 million to 14.7 million people. Including those with
undiagnosed disease, diabetes mellitus currently affects approximately 18.2 million
individuals in the United States; the majority of which is type II diabetes. Between
1983 to 2003 the prevalence of type II diabetes increased from 5.9% to 13.8%
[145].

It has been predicted that by the year 2050, 29 million American will be

diagnosed with diabetes which will be 165% more than in the year 2001 [146].
Of great concern is the growing number of children and adolescents now
being diagnosed with type II diabetes related to obesity [3].

The link between

obesity and type II diabetes has caused some to suggest using the term “diabesity”
to better describe the current epidemic. Developing type II diabetes rises with
increasing body weight, and is about 5-10 times greater in those having a body mass
index of 30 or above than in those with a body mass index below 25. Those with a
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body mass index of 30 or above are classified as obese [4, 9]. There are believed to
be more than 250 million obese adults worldwide.
This does not bode well for the future. Currently an estimated 46 to 49
million adults in the US may have insulin resistance and it is predicted that one in
four of them will develop type II diabetes [147]. Diabetes is predicted to reach
epidemic proportions not only in the United States but throughout the world. The
World Health Organization (WHO) predicts that the number of people with diabetes
will double within just one generation, from 150 million in 2001 to an estimated
300 million in 2025. The developing world is expected to have the greatest increase
in diabetics. In developed countries diabetes is predicted to rise by a total of 41%
between 1995 and 2025 while in developing countries it is predicted to rise by 170
within the same time period [148].
The cause of diabetes type II is not fully understood and is linked with not
only obesity as discussed above, but also the lack of exercise, and hyperlipidemia.
Obesity is associated with a low-grade state of inflammation, probably as a
consequence of the secretion of pro-inflammatory cytokines by adipocytes that may
underlie the insulin resistance [149].

Early in 2001, researchers identified a

hormone called resistin which might explain the obesity-diabetes link at a
biochemical level [150]. Resistin more recently has been determined to have a
potential role in atherogenesis [151].
Two possible mechanisms responsible for insulin resistance include the
activation of protein kinase C (PKC) [152] and elevated TNF-a [153], Both of
these mechanisms affect the insulin receptor by deactivating it and interfering with
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glucose uptake into the cell [154].

The insulin receptor is composed of two

subunits which extend through the cell membrane. When insulin binds to the
subunits, it turns on the enzyme tyrosine kinase which causes a series of
phosphorylations to occur on the tyrosine resides.

The phosphorylated tyrosine

activates second messengers causing the translocation of glucose into the cell [155].
PKC in the cell is activated when there are elevated free fatty acids. The activated
PKC causes the phosphorylation of serine and threonine residues on the insulin
receptor, not tyrosine. When this occurs glucose is not translocated from the blood
stream and into the cell via the insulin receptor. TNF-a secretion increases due to
weight gain and also negatively affects the insulin receptor [156]. It stimulates
phosphatases in the cell to take off the phosphate groups on the tyrosine residues
which again inhibits the translocation of glucose into the cells leading to
hyperglycemia [157, 158].
The diabetic’s lipoprotein profile is characterized by changes in lipoprotein
concentrations and composition [159]. On average, the plasma total cholesterol of
diabetics is similar to non-diabetics. However, type II diabetes is associated with a
dyslipidemia that includes increases in plasma LDL, small dense LDL, VLDL,
lipoprotein(a), and a decrease in HDL [160].

This creates and even more

atherogenic lipoprotein profile in the diabetic.
Patients with insulin resistance and type II diabetes also characteristically
have elevated postprandial triglyceride-rich lipoproteins compared to non-diabetics.
Fasting hypertriglyceridemia levels have been demonstrated to predict this
abnormal postprandial response to a dietary fat load. A strong correlation exists
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between plasma insulin and the postprandial TG response to a fat meal, as well as to
the postprandial levels of large YLDLs and chylomicron (CM) remnants. In the
fasting state, increased plasma insulin, a marker of insulin resistance, is also related
to increased fasting plasma levels of large VLDL and CM remnants [161-168].
Diabetes, types I and II, have been shown to significantly increase the extent
and clinical complications of atherosclerosis [169, 170]. Initially the view was that
many of the pathologic effects of diabetes were from the condition of
hyperglycemia itself. However, it was noted that increased lesion development was
already apparent upon diagnosis of diabetes indicating that these lesions were most
likely developing during the euglycemic pre-diabetic state. Clinical trials have
documented that a reduction in LDL cholesterol significantly reduces the risk of
CVD in diabetics while a reduction of blood glucose levels has a relatively small
effect on atherosclerosis [170].
Since the oxidative modification of LDL is an important initiator of
atherosclerosis it was important to determine whether an increase in oxLDL was
present in diabetics.

Oxidative stress has been demonstrated to be elevated in

diabetics [171] as indicated by decreased plasma levels of vitamins E and C, and
increased serum MDA [172] and urinary F2-isoprostanes [173].

Fatty acid

hydroperoxides, another indicator of oxidative stress, are elevated 2 to 3 fold.
Diabetics also have elevated levels of autoantibodies to oxLDL [174] and the
resulting immune complexes between oxLDL molecules and their autoantibodies
are more readily taken up by macrophages causing the accumulation of cholesteryl
esters and an increase in the release of 11-1 and TNF-a. In addition, the LDL of
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diabetics has a higher affinity for proteoglycans ex vivo [175, 176] and appears to
be more prone to oxidative modification than that of non-diabetics [177].

The

source of free radicals in diabetes is not completely understood but cells may
produce increased superoxide when exposed to glucose and there may be diabetes
associated mitochondrial dysfunction increasing mitochondrial generation of ROS.
Elevated glucose has also been shown to increase the expression and activity of 12lipoxygenase in SMCs [178]. Therefore, while the greater risk for and development
of atherosclerosis in diabetics could be due to a number of factors including
dyslipidemia, hyperglycemia, and insulin resistance, increased oxidative stress
appears to play an important role.
One of the effects of increased oxidative stress may be to exacerbate another
process known as glycation. Chronic exposure of proteins to increased glucose
concentrations in diabetics leads to the formation of advanced glycation endproducts (AGEs) [179].

Oxidation and nonenzymatic glycation are mutually

reinforcing processes leading to glycoxidation.

All three processes, glycation,

glycoxidation, and oxidation are complex interrelated processes.

For example,

glycated LDLs are more oxidizable than nonglycated LDLs and increased lipid
oxidation appears to be sufficient to cause AGE formation in euglycemic animals
[180].

Carboxymethyl lysine (CML), an irreversible advanced stage molecular

structure generated through glycoxidation, [181] is increased in the atherosclerotic
lesions of diabetics.

One study demonstrated that the development of

atherosclerosis is synergistically promoted by glycoxidation and lipid peroxidation
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of LDL [182]. This accelerated atherosclerosis is a major cause of morbidity and
mortality in diabetics.
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CHAPTER III

SCAVENGER RECEPTORS

Since it was determined that oxLDL was the ultimate source of cholesterol
that accumulated in developing foam cells, investigators initially thought that
foam cell formation was mediated by the LDL-R.

However, patients without

functional LDL-Rs had early atherosclerosis with foam cells similar to those that
developed in people with functional LDL-Rs, demonstrating that functional LDLRs were not required for foam cell formation.

In addition, macrophages

completely lacking LDL-Rs could become foam cells. The uptake of oxLDL by
macrophages was eventually demonstrated to take place by way of a “scavenger
receptor” [183].

Unlike the LDL-R, scavenger receptors (SRs) do not down

regulate in the presence of high LDL concentrations.

Macrophages may

therefore continue to take up oxidized LDL until they become engorged with
stored cholesterol.
The expression of SRs is modulated by various growth factors,
inflammatory

cytokines,

chemokines,

lipids,

cholesterol

and

modified

lipoproteins, all of which are present within the atherosclerotic lesion [184], SRs
were originally implicated in the pathological deposition of cholesterol in the
foam cells of atherosclerotic lesions through receptor-mediated uptake of
modified LDL.

However, other functions of SRs, including endocytosis,

phagocytosis, adhesion, and signal transduction triggered by the binding and
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uptake of modified LDL, have subsequently been determined to also be involved
in the development of atherosclerosis.
There are six different classes of SRs. All are similar to the LDL-R in that
they are cell surface transmembrane receptors. The name scavenger receptor was
well chosen, because SRs recognize a spectrum of structurally unrelated ligands
and although each scavenger receptor shows a broad specificity that often
overlaps that of another scavenger receptor, a clear preference for certain ligands
by each receptor is apparent [184]. While the ligands are themselves unrelated
they all share one similarity in that they are all negatively charged
macromolecules. OxLDL is one such negatively charged macromolecule. Other
modified lipoproteins recognized by scavenger receptors, include acetylated LDL,
glycoaldehyde, which is an AGE-modified LDL, and nitrate-modified LDL. SRs
also bind other ligands such as thrombospondin, collagen, phosphatidylserine,
liposomes, bacterial components such as endotoxin, and apoptotic cells [184]. In
vivo , oxLDL binding and uptake by macrophages appears to be the most relevant

for the atherosclerotic process.
SRs also participate in the recognition and clearance of apoptotic cells and
bacteria [185].

Removal of dead or apoptotic cells is important both for

embryological development and for maintaining tissue homeostasis.

The

recognition of oxLDL by SRs may be explained by the structural similarities
between cell membranes and lipoproteins.

Both consist of phospholipids,

cholesterol, and (glyco)protein. Oxidative damage to a lipoprotein particle may
create epitopes that resemble the epitopes expressed by cells that undergo
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apoptosis or by senescent red blood cells [186].

Thus, macrophages are

responding in a protective manner by clearing the tissues of dead cells.
The first scavenger receptor was discovered on macrophages and was
called scavenger receptor A (SR-A).

The molecular characterization of SR-A

took place in 1990 when it was finally cloned [187]. In recent years, several new
members of the scavenger receptor family, such as CD36, SRB1, and CD68 have
been discovered on macrophages and have also been cloned on the basis of their
ability to recognize modified lipoproteins [188, 189],
The receptor focused on in this study was the first scavenger receptor
originally identified as an endothelial cell scavenger receptor [190, 191]. Based
on sequence data showing that the molecule has a long C-terminal extracellular
domain belonging to the C-type lectin family, the molecule was termed LOX-1
for lectin-like oxLDL receptor-! [191]. LOX-1 is a type II membrane protein
classified as a class E scavenger receptor that has been demonstrated to act as a
cell-surface receptor of oxLDL [192, 193]. It does not share any homology with
any other of the known SRs. In addition to the extracellular C-type lectin domain,
LOX-1 consists of a hydrophobic transmembrane domain and a cytoplasmic Nterminal domain. Although the calculated mass of this protein is about 3 1 - 3 2
kDa [192-194], it is found endogenously as a 40 kDa precursor form with Nlinked high mannose carbohydrate chains and a 48 - 50 kDa mature form due to
further glycosylation [193]. This is the result of post-translational modification of
four potential N-linked glycosylation sites located on the C-terminal domain. The
N-linked glycosylation of LOX-1 appears to be necessary for adequate
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transportation to the cell surface and efficient ligand binding [193]. The lectin
domain is the functional domain that recognizes LOX-1 ligands and the Cterminal end residues and several conserved positively charged residues spanning
the lectin domain are essential for oxLDL binding. In the N-terminal cytoplasmic
domain there are several potential phosphorylation sites. An unknown protease is
able to cleave the N-terminal amino-acids at two cleavage sites, located in the
membrane proximal extracellular domain, releasing soluble LOX-1 (sLOX-1) into
the bloodstream. The LOX-1 receptor is not only present on the endothelium of
vascular rich organs (liver, lung, brain, placenta), the aorta, coronary and carotid
arteries, but also on macrophages and vascular SMCs in atherosclerotic lesions,
including those of humans [193, 195],
It has been demonstrated that LOX-1 promotes the binding, internalization
and degradation of oxLDL, [196], lysophosphatidylcholine, and oxidized fatty
acids. The binding of oxLDL to LOX-1 may trigger the activation of the NF-kB
signal transduction pathway [197]. Binding experiments have demonstrated that
native LDL and acetylated LDL do not compete with LOX-1 for uptake of
oxLDL [191, 196].

LOX-1 expression has been shown to be upregulated by

minimally oxidized LDL but not extensively oxidized LDL.

TNF-a [198],

transforming growth factor beta (TGF-|3) [194, 199], angiotensin II [200] and
shear stress also upregulate LOX-1.
The binding of platelets to LOX-1 enhances the release of endothelin-1
from ECs inducing endothelial dysfunction and promoting the atherogenic
process [201].

LOX-1 is also a key factor in oxLDL-mediated monocyte
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adhesion to human coronary artery endothelial cells [202]. LOX-1 has the ability
to capture leukocytes under physiologic shear stress suggesting that it functions as
a vascular tethering ligand [203]. C-reactive protein (CRP) also enhances
endothelial LOX-1 expression [204] and increases both human monocyte
adhesion to endothelial cells and oxLDL uptake by these cells. Heparin-binding
epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for
vascular SMCs, also induces LOX-1 expression in cultured bovine aortic SMCs
[205],

Homocysteine, an atherogenic amino acid believed to exert its effects

through oxidative stress, enhances endothelial LOX-1 gene expression in aortic
ECs.

The antioxidant N-acetylcysteine (NAC) suppresses this enhanced

endothelial LOX-1 gene expression [200].

LOX-1 is also known to bind

apoptotic cells and oxidized red blood cells.
OxLDL stimulated LOX-1 expression in human coronary artery ECs is
downregulated by pre-treatment with statins [195, 206]. A high concentration of
statins (10 uM) is more potent than a low concentration (1 uM) in downregulating
LOX-1. LOX-1 on ECs induces reduction of nitric oxide (NO) release and upregulation of adhesion molecules, thereby contributing to the development of
atherosclerosis [207]. Antisense to LOX-1 mRNA decreases LOX-1 expression
and the subsequent expression of the adhesion molecules, VCAM-1, ICAM-1 and
the selectins [206]. Monoclonal antibodies against LOX-1 can inhibit oxidized
LDL binding to cultured bovine aortic ECs by 50 to 75%.

This indicates that

LOX-1 may play an important role in the uptake of oxLDL from the bloodstream
and the development of atherosclerotic lesions.
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The presence of LOX-1 has been demonstrated in both animal models of
atherosclerosis and human atherosclerosis. LOX-1 ligand levels have been shown
to be significantly elevated in the plasma of Wantanabe heritable hyperlipidemic
rabbits [208]. In addition, increased expression of LOX-1 has been demonstrated
in the initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits
primarily within the aortic intima at the earliest stages of lesion development and
most prominently in the ECs of the lesions. However, even the ECs in the non
lesion areas exhibited distinctive LOX-1 immunoreactivity in these animals [209]
demonstrating that the hyperlipidemia itself increased the LOX-1 expression.
LOX-1 has also been shown to be significantly increased in diabetic rat aorta with
the most immunoreactivity in ECs, particularly those in the bifurcations of artery
branches from the aorta [210].

Studies have also shown that the monoctye-

derived macrophages of humans with type II diabetes also over express LOX-1.
Diabetics, as discussed previously, have dyslipidemia but not necessarily
hyperlipidemia.

Even without hyperlipidemia, diabetics have markedly

upregulated LOX-1 expression. LOX-1 has been shown to bind not only oxLDL
in diabetics but also AGEs, the non-enzymatically glycosylated proteins which
accumulate in the vascular tissues of the aging and diabetic populations [211].
In cultured aortic ECs, streptozotocin-induced diabetic rat serum and
AGE-bovine serum albumin (BSA) induced LOX-1 expression, while control rat
serum with only high glucose did not. This suggests that glucose alone is not
responsible for the induction of LOX-1 expression on ECs but that plasma
proteins that have undergone glycosylation are the more likely culprits [212]. In
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contrast,

in

vitro

studies

using

human

monocyte-derived

macrophages

demonstrated that incubation with glucose would enhance both LOX-1 gene and
protein expression in a dose- and time-dependent manner. Antioxidants, PKC,
mitogen activated protein kinases (MAPKs), nuclear factor-kappaB (NF-kB), and
activated protein-1 (AP-1) inhibitors all were able to abolish the induction of
LOX-1 gene expression in macrophages by glucose. [213]. Whether it is glucose
alone that increases LOX-1 expression, as seen in human monocyte-derived
macrophages, or whether it takes AGE-modified plasma proteins to increase
LOX-1 expression as seen in cultured aortic ECs, both processes are indicative of
the relevance of the study of LOX-1 in relation to diabetic atherosclerosis.
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CHAPTER IV

THE SYRIAN FXB HAMSTER

Animal models of human diseases are often used in experimental studies because
environmental and genetic backgrounds can be strictly controlled in animal models. This
control is difficult when studying human disease in humans as environmental and genetic
backgrounds differ from individual to individual and population to population. Recently
much of the animal research has used gene “knockouts” where targeted genes are deleted
from the animals. However, scientists must be cautious in their interpretation of results
from gene knockout animals since gene deletions may have secondary phenotypic effects
and are not tissue specific.

Additionally, gene deletions may cause compensatory

changes in the expression of other genes in these animals and this may also confound the
results.
The Syrian hamster, M esocricetus auratus, has been used extensively as an
experimental animal model since 1930 when hamsters captured in Syria where bred at
Hebrew University. The normal life span of the Syrian hamster is up to 3 years. While
the hamster is classified as an omnivore and is capable of predation, some of the
structural features of its gastrointestinal tract and some features of its feeding behavior
are more similar to that of an herbivore [214], Hamsters have a rigid and regular two
hour feeding schedule, feeding 12 times throughout the day and night in a 24 hour period.
They will normally consume about 2.5 calories/lOOg at each 2 hour interval when fed ad
libitum or about 30 calories/1 OOg per day for a sedentary hamster.

Hamsters have
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limited physiologic ability to withstand food deprivation.

Their basic response to a

shortage of food is to reduce their energy expenditure rather than increase their food
consumption when food again becomes available. Fasting for as short as 24 hours may
induce starvation anorexia or may decimate the bacteria and protozoa in the forestomach
and cecum necessary for digestion.

Weight loss greater than 22% may cause

hypothermia, unconsciousness and whole-body tremors [215, 216].

Lipoprotein Metabolism
Hamsters have long been used as an animal model for the study of lipoprotein
metabolism [217] since their lipoprotein metabolism has many attributes in common with
humans [218, 219]. Hamsters have relatively high serum LDL concentration when
compared to mice and rats [220].

In the hamster, as in humans there are appreciable

levels of LDL as well as HDL [221].

And although unlike humans, HDL is the

prominent lipoprotein present in hamster plasma, at least one third of the cholesterol is
associated with the LDL fraction under normal dietary conditions [222]. The apoprotein
B concentration is sevenfold greater in hamsters than in rats. In rats, 47% of apoprotein
B is associated with LDL, while in hamsters, 70% of apoprotein B is associated with
LDL [223, 224], In general the apoprotein profile of the hamster has many similarities to
that of humans. However, there is a difference in apoE expression between humans and
hamsters. ApoE is found in the LDL fractions of hamsters but very little is found in the
LDL fractions of humans.

ApoE is also a more prominent constituent of VLDL in

hamsters than in humans.

Overall the plasma lipoprotein profile of humans in more

analogous to hamsters than to mice or rats [225].
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Unlike livers from rat or mouse, the liver of the Syrian hamster secretes only
apoB-100 containing VLDL, as is the case in humans [226]. Apoprotein B-48 containing
lipoproteins are of intestinal origin only [227] in hamsters and in humans.

This tissue-

specific expression of apoB-100 by the liver only and apoB-48 by the intestine only is a
distinct advantage of the hamster model [227, 228] over the mouse and rat model.
Hamsters have also been shown to express plasma cholesteryl ester transfer protein
(CETP) activity which is regulated by the level of cholesterol-containing lipoproteins in
plasma as is the case in humans [229, 230]. Rats do not express CETP activity [231],
The hamster LDL-R receptor gene has been isolated and characterized and shows
strong sequence and structural similarities to the human gene [232],

The receptor-

dependent transport of LDL in the hamster is also similar to humans. In the hamster, the
liver is the major site for the removal of plasma LDL, accounting for 73% of the LDL
degradation. This is due to both the high rate of receptor-mediated transport per gram of
tissue and the large size of the liver. Most of the LDL degradation is mediated by the
LDL-R following saturation kinetics.
In human lipoprotein metabolism, the concentration of circulating LDL is
determined by the rate of LDL formation relative to the rate of receptor dependent LDL
removal from the plasma [233]. When dietary intake of cholesterol and triacylglycerol is
minimal and little lipid is reaching the liver in the chylomicron remnant, the rate at which
LDL cholesterol is being produced and entering the plasma is low relative to the rate at
which LDL can be removed from the plasma by receptor-dependent transport. This is
also true for the hamster where the LDL production rate is only about 150 ug/h while the
maximal achievable rate of receptor dependent removal is about 700 ug/h [234]. In the
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hamster, as in humans, the liver has a relatively low rate of cholesterol synthesis. The
extensive work of Dietschy, Spady and co-workers has shown that the level of hepatic
cholesterol synthesis in hamsters is equivalent to that found in humans, approximately 9 10 mg cholesterol/day/kg body weight [234, 235], Rats and mice synthesize
approximately 150 mg cholesterol/day/kg body weight, another reason why they are not
good models of human lipoprotein metabolism [236],
The extrahepatic tissues of the hamster however, have high rates of cholesterol
synthesis and may synthesize most of the cholesterol they need. Therefore, most of the
apoprotein B-100 that is secreted from the liver in VLDL is returned to the liver carried
either in VLDL remnants or in LDL. Relatively little is delivered to the peripheral organs
[237]. Other animal models in which the rate of cholesterol synthesis in the liver is low
compared to cholesterol synthesis in the whole animal are guinea pigs, pigs and several
species of monkeys and baboons [236], However, these species are not as easy to handle
or as inexpensive as the hamster. They also have other dissimilarities to human
lipoprotein metabolism which makes them unacceptable as models for studying human
lipoprotein metabolism.

Response to High Fat Diet Challenge
Hamsters are also similar to humans in their response to increases in dietary
cholesterol in that both will demonstrate an increase in serum LDL cholesterol (Jansen,
1989). When fed an appropriate diet, the hamster presents a more human-like lipoprotein
profile than do many other rodent species [230, 238]. Hamsters fed a hyperlipidemic diet
closely parallel the human type IV and type V hyperlipidmias in which serum triglyceride
concentrations are increased [239],
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In the absence of dietary cholesterol the VLDL + LDL/HDL ratio in the hamster
is below 1.0 but this ratio increases after cholesterol feeding to 2.6 in the FiB hamster
strain [240],

Rats and mice, on the other hand, will respond to increases in dietary

cholesterol by activating bile acid synthesis. Therefore, they primarily down-regulate
hepatic synthesis and up-regulate hepatic bile acid production so that the plasma
lipoprotein concentration remains relatively unchanged [236]. This response is distinctly
different from humans, again making rats and mice poor models for dietary cholesterol
challenge studies. Again, other animal models that behave similarly to humans in
response to a dietary cholesterol challenge include guinea pigs, pigs, and several species
of monkeys and baboon. An increase in cholesterol intake by 5 - 10 times their synthesis
rate provides a rigorous cholesterol challenge to any of these animal models [236]. But
again, the hamster is the more inexpensive model to feed and the easiest to handle
making them most desirable.
On average, humans take in approximately 3 - 5 mg cholesterol/day/kg/ body
weight which is equivalent to 50% or less of that synthesized. A comparable dose of
dietary cholesterol in hamsters is achieved by adding only 0.1 - 0.3% cholesterol to the
hamster’s diet. If cholesterol is added at an amount higher than 0.3%, changes occur in
liver biochemistry and plasma lipoprotein concentrations that do not have any relevance
to the regulation of lipoprotein concentrations in humans [236],

In addition to

cholesterol, high fat must be added to the diet in order for hamsters to develop combined
hyperlipidemia.
alone [241].

Cholesterol alone will not have this effect and neither does high fat

The addition of cholesterol alone to the diet causes a dose-dependent

increase in the level of cholesterol esters in the liver, a progressive suppression of LDL
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receptor activity, and small increases in the LDL production rate.

The addition of

triacylglycerol containing saturated fatty acids to cholesterol containing diets lowers the
concentration of hepatic cholesterol esters, further suppresses receptor activity,
significantly increases the LDL production rate and as a consequence of these events,
markedly raises the plasma LDL level [234, 235, 242, 243]. This is similar to the
naturally occurring dietary situation in a large portion of the human population. The
addition of saturated fat in the diet also reduces the uptake of cholesterol into the tissues
through the LDL-R pathway [234, 242],
It takes about 4 -5 weeks for approximately 100 pools of LDL to be turned over in
the hamster.

This is when the hamster reaches a steady state in the distribution of

unesterified and esterifled cholesterol in the liver, the level of hepatic LDL receptor
activity, the size of LDL production, and the concentration of LDL in the plasma. In
humans this probably takes longer than 3 months to achieve [244],

Model for Human Atherosclerosis
While most hamster strains respond to high cholesterol diets with increased
plasma LDL, one strain, the Syrian FiB hamster is associated with an increased
susceptibility to atherosclerosis due to a deficiency in LPL activity. The deficiency of
LPL activity in the FiB hamster causes an accumulation of chylomicrons and to a lesser
extent VLDL [245]. The absence of functional LPL is one of the underlying causes of
type 1 hyperlipoproteinemia in humans and it is possible that cholesterol may exert direct
effects on LPL gene expression.
In addition, the hybrid FjB hamster requires relatively low levels of dietary
cholesterol to develop aortic atherosclerosis compared to other non-hybrid strains [246].

44

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

A diet containing 0.2% cholesterol and 10% coconut oil can cause fatty streak formation
in the ascending aorta within 2 months [238].

Hypercholesterolemic diet-induced

atherosclerosis in the hamster model is confined initially to a lesion-prone area along the
inner curvature of the aortic arch [230, 238]. Prolonged consumption of an atherogenic
diet results in the development of lesions throughout the aorta [245], The lesions are
similar to those found in humans [247, 248] characterized by the infiltration of
monocytes, which become lipid-filled macrophage foam cells [246]. Within 12 months
these early aortic lesions can develop into complex advanced plaques resembling human
lesions, with a fibrous cap of SMCs, connective tissue matrix and a necrotic core
containing cholesterol crystals [249].

Rats are resistant to atherosclerosis [250] and

atherosclerotic lesions formed in any of the mouse models of atherosclerosis do not
progress to the stage in which lesions promote the clinical manifestations observed in
humans.

Several species of rabbits develop atherosclerosis on high fat diets but the

rabbit’s cholesterol metabolism is different from that of humans and they develop a
‘cholesterol storage disease’ with lesions that are not the same as that of humans [251].

Model for Diabetic Accelerated Atherosclerosis
A major limiting factor in studying the mechanisms responsible for accelerated
atherosclerosis in diabetes has been the lack of a suitable animal model.

Diabetes

appears spontaneously in some animal species, and several genetic models have been
developed in rodents.

However these animals are poor models of human diabetic

atherosclerosis. The most successful approach to developing a diabetic atherosclerosis
model has been to superimpose diabetes on a current atherosclerosis animal model such
as the hyperlipidemic Syrian hamster. This has previously been accomplished by either
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removing the insulin producing B-cell via pancreatectomy or by the injection of a B-cell
toxin such as alloxan or streptozotocin (STZ).

STZ Induced Diabetes
STZ, a natural compound isolated from the gram positive bacterium Streptomyces
achromogene, was discovered in 1960 as a new antibacterial antibiotic. It is an alkylating

agent consisting o f a methyl-nitrosurea side group attached to carbon-2 of D-glucose
[252]. The glucose moiety allows for preferential uptake of STZ into B cells via the
glucose transporter (GLUT)-2 [253, 254].
STZ exists as a mixture of alpha and beta anomers [255]. Upon dissolution of
powdered STZ in an aqueous buffer, equilibrium between the two anomers is complete
within 2 hours at room temperature with a nearly equimolar mixture of the anomeric
forms [256]. STZ is unstable in unbuffered aqueous solutions, but stable for several days
in a buffered aqueous solution with a pH of 4.0.
STZ has been used to induce diabetes mellitus in many different experimental
animal models including the rat, mouse, guinea pig, monkey, pig and Chinese and Syrian
hamsters [257-267] due to its selective pancreatic P-cell toxicity. However, most species
have a high acute mortality to STZ injection, whereas Syrian hamsters show a high
percentage of survival after STZ injection [268]. Han et al [269] determined that a single
injection of 40 mg/kg of STZ was the appropriate dose to induce hyperglycemia in the
APA strain of the Syrian hamster without nephrotoxicity although approximately 10% of
the injected hamsters fail to develop hyperglycemia.
There is over 20 years of evidence supporting B cell death in STZ treated rodents
[270-272]. STZ causes DNA strand breaks which then activate poly ADP-ribose
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synthetase, an enzyme that polymerizes the ADP-ribose moiety of NAD to form poly
ADP-ribose. This causes a lethal depletion of nicotinamide adenine dinucleotide (NAD)
in the [3-cells [273-278], STZ has been shown to directly methylate DNA producing not
only DNA strand breaks, but also alkali-labile sites, DNA adducts, chromosomal
aberrations, micronuclei, sister chromatid exchanges, and cell death [279], Free radicals
may also be involved in the DNA and chromosome damage produced by STZ [280],
Gille et al. [281] demonstrated that STZ increases the generation of reactive oxygen
species in murine islet cell cultures.

STZ not only modulates energy metabolism by

decreasing the amount of reducing equivalents such as NADH and NADPH but also by
modulating oxygen metabolism in cells by reducing their antioxidant capacity and
increasing mitochondrial ROS formation. Further aggravating the situation is the fact
that intracellular metabolism of STZ also yields nitric oxide which precipitates additional
DNA strand breaks [282], The ROS induced damage of proteins, lipids and DNA, as
well as the depletion of energy, all contributes to the death of the (3-cells.
There are apparently essential characteristics that make the mature [3-cell
particularly susceptible to toxins such as STZ, one of which is the expression of GLUT 2.

However, the precursor population for both endocrine and exocrine tissue in the

pancreas is not susceptible to damage by STZ [283],

This is most likely due to an

insufficient expression of GLUT-2 on the immature cells.
As stated previously, Syrian hamsters of the APA strain are known to enter a
marked and continuous diabetic state after a single injection of STZ without severe toxic
effects. STZ-induced hamsters may be able to maintain this diabetic state due to the
proliferation of immature precursor cells that are not affected by the STZ. This was
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demonstrated by Wang et al. [284] in newborn rats injected with 100 ug/g of STZ. They
found that while the STZ dramatically reduced the number of P-cells in islets it had little
effect on the number of P-cells found in aggregates of less than six endocrine cells.
Presumably, these small aggregates are neogenic and are derived from differentiation of a
precursor cell population. The lack of an effect on these aggregates suggests that they
may be a less differentiated, immature P-cell population not effected by STZ. Another
possibility is that hyperglycemia may also play a role in stimulating P-cell replication
after STZ administration.

Glucose is a well-known stimulus for proliferation of pre

existing P-cells [285]. Movassat et. al. [286] demonstrated that hyperglycemia may also
play a role in stimulating P-cell replication after STZ administration in newborn rats with
partial pancreatectomy.

However, whether the hyperglycemia was influencing

preexisting mature P-cells or new p-cells arising from precursor cells was not determined.
More recently, Finegood et. al. [283] demonstrated that prior STZ treatment did not
inhibit pancreas regeneration after 90% pancreatectomy in rats. He concluded that there
was no evidence that hyperglycemia enhanced the formation of new endocrine cells from
ductal precursor cells but that the possibility that moderate hyperglycemia had a trophic
influence on preexisting p-cells in the form of hypertrophy or replication could not be
excluded. However he did find that severe hyperglycemia, or something associated with
it, appeared to inhibit the development of the endocrine cell mass.

Rosenberg [287]

postulated that islet-cell regeneration in the diabetic hamster pancreas could be induced
by a local growth factor(s). Whatever the reason, Takatori et al. [288], in a functional and
histochemical analysis on pancreatic islets of APA hamsters with STZ-induced
hyperglycemia and hyperlipidemia, found that these hamsters could remain in a diabetic
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state because resident P-cells in the islets proliferated even after STZ injection and that
most degenerated cells continued to maintain low levels of insulin secretion.
One problem with the use of STZ to induce the diabetic state is that the
efficacy of STZ is highly variable between species, strain, age and laboratory. Even in
the same species of animal receiving the same dose of STZ the results are widely variable
[289], This limits the predictability of the effects of STZ in inducing diabetes. Therefore
other methods of inducing diabetes and insulin resistance are currently being
investigated.

High Fat Diet Induced Insulin Resistance
Recently it has been determined that the high fat-fed Syrian Golden hamster
without STZ injection, in addition to being a good model of human hyperlipidemia and
exhibiting

a

significant

weight

gain,

also

exhibits

hyperinsulinemia

and

hypertriglyceridemia which are characteristic of the profile often observed in obese
insulin-resistant and/or type 2 diabetic patients [241].

The high fat diet load not only

causes impairment of insulin secretion but also leads to insulin resistance making the
high fat-fed hamster a model of nutritionally-induced insulin resistance [290].

The

insulin resistance is accompanied by a marked increase in intestinal apoB48 particle
production which is an integral feature of the insulin resistant state. Peripheral glucose
disposal stimulated by insulin is inhibited by the elevated levels of plasma free fatty acids
in man [291, 292],

The high-fat fed Syrian Golden hamster also has a significant

reduction in whole body glucose disposal and a reduction in insulin suppression of
hepatic glucose production [290].
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High Fructose Diet Induced Insulin Resistance
Another model of nutritionally-induced insulin resistance is the high fructose-fed
hamster.

High fructose feeding alone for a 3-week period induces significant

hypertriglyceridemia characterized by the overproduction of intestinal apoB48-containing
lipoproteins in both the fasting and postprandial states [293]. Hyperinsulinemia and the
development of whole body insulin resistance in the high fructose-fed Syrian golden
hamster, similar to the high-fat fed model, is again due to the overproduction of apoB48
particles.

However, in contrast to the high-fat fed model, the fructose fed hamster

induces insulin resistance in the absence of significant weight gain [294]. The high fat
high fructose fed hamster is therefore a good animal model for the study of the treatment
of diabetic dyslipidemia [226].

This model also demonstrated insulin resistance as

judged by elevated insulin levels during an oral glucose tolerance test (OGTT) indicating
that it may be a useful model for the study of the interaction of diabetes and
atherosclerosis. There may be less variability in response to high-fructose than there is to
STZ.

Additionally the use of fructose eliminates the hamster deaths related to the

toxicity of STZ.
In conclusion, the hamster is a useful small animal model that simulates the
interaction of diabetes and atherosclerosis because hyperglycemia and atherosclerosis can
be easily induced and because the lipoprotein metabolism of hamsters has many attributes
in common with humans.

Additionally, hamsters develop atherosclerotic lesions and

other diabetic complications similar to humans [295]. In the following study, combined
diabetes and atherosclerosis was studied in STZ injected, high-fat fed Syrian FiB
hamsters.
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CHAPTER V

MATERIALS AND METHODS

Animals, Diets, and Experimental Design
Sixty male golden FiB Syrian hamsters (M esocricetus auratus), 9 weeks old,
weighing between 87 grams (g) and 106 g, were obtained from Biobreeders (Watertown,
MA).

Hamsters were housed individually in rodent cages under environmentally

controlled conditions of 20 ± 1° C at 30% to 60% humidity on a 12-hour/12-hour
light/dark cycle with a d libitum access to food and water. After one week of acclimation,
animals were randomly divided into four experimental groups (Figure 1):
N - non-lipidemic/non-glycemic hamsters fed Purina 5001 standard rodent chow
pellets containing 0.03% cholesterol and 4.5% fat (n=14);
L - lipidemic hamsters with lipidemia induced with 0.062 kgs purified cholesterol
(0.25%) dissolved in 3 liters of hot coconut oil (10%) wt/wt (Research Diets, Inc.,
New Brunswick, NJ) and added to 22.7 kgs Purina 5001 rodent meal with the
same formula as the standard rodent chow pellets (n =14).
G - glycemic hamsters fed standard chow with glycemia induced by one
intraperitoneal injection of 40 mg/kg body weight streptozotocin (Stz) (Sigma
Chemical, St. Louis, MO) freshly dissolved in 0.1M citrate buffer pH 4.5 (n =16);
and
L+G - lipidemic/glycemic hamsters with lipidemia induced with the same diet as
group L and glycemia induced with the same Stz injection as group G (n =16).
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To prepare the high-fat diet, additional water was added to the final meal mix to
achieve a moist consistency. This was compacted to a 2” depth in large Tupperware
containers and frozen until just prior to feeding when it was defrosted and cut into
squares.
All hamsters were weighed prior to the start of the study (time 0) and at 1, 2, 3,
6, and 8 weeks after the start of the study. All experimental procedures were performed
in accordance with protocols approved by the Institutional Animal Care and Use
Committee at the University of New Hampshire (IACUC approval #010702). Hamsters
administered STZ had 5% glucose added to their water for two days in order to
counteract the release of insulin from the dying beta cells and prevent diabetic shock.
After Stz injection one hamster in the G group and four hamsters in the L+G group died.
After ten weeks, seven hamsters from each group were weighed, fasted overnight,
and anesthetized with an intraperitoneal injection in the lower right abdominal quadrant
of Ketamine-HCL:xylazine (20mg:8mg per 100 grams body weight) in a 1 cc tuberculin
syringe (Becton Dickinson & Co., Rutherford, NJ). The hamsters were then euthanized
by exsanguination.

A small incision was made in the abdominal wall, through the

peritoneum. The heart was exposed by making a longitudinal cut up to the sternum and
through the ribs left of the sternum. Blood was withdrawn from the left ventricle with a
22 gauge 1 inch needle on a 3 cc syringe and was immediately aliquoted into one 200 ul
Microvette 200 Z-gel tube for serum collection and two 1.3 mL Microtubes (Sarstedt,
Newton, NC) containing 1.6 mg potassium-EDTA/ml of blood for plasma collection.
Plasma samples were gently inverted several times and immediately spun at 1,500 x g for
15 minutes in an Eppendorf 5415 C microfuge (Brinkman Instruments, Inc., Westbury,
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NY). Serum samples were allowed to clot for 20 to 30 minutes and then spun as above.
After centrifugation, serum or plasma was removed and aliquots for lipids, glucose, and
insulin analysis were placed on ice. All aliquots were frozen at - 80° C (Revco Scientific
Inc., Asheville, NC) within 4 hours until analyzed.
To eliminate remaining blood cells and plasma proteins the vasculature of each
hamster was immediately perfused with phosphate buffered saline (PBS) pH 7.4 by the
insertion of a 21 gauge 1 inch butterfly needle into the left ventricle and a cut in the right
atrium to allow an outlet for the solution.

The saline was perfused for 5 minutes at the

physiologic pressure of 100 to 120 mm Hg.

Following the saline perfusion, four

hamsters from each group were put in a plastic bag on ice. The remaining three hamsters
from each group were perfused with 10% neutral buffered formalin (NBF) for 10 minutes
under the same conditions as used for the saline. After 10 minutes of fixation in situ, the
hamsters were put in a plastic bag on ice. The four hamsters from each group that were
perfused with PBS only were dissected to remove the heart and aorta and a section of
liver and kidney which were then placed in a vial and flushed with nitrogen gas before
being snap frozen in liquid nitrogen and stored at minus 80° C. The three hamsters that
were additionally perfused with NBF were also dissected to remove the heart, and aorta,
and sections of liver, kidney and pancreas. The heart and aorta were pinned out at in situ
length and all tissue was immersed in NBF overnight. After overnight fixation the aortic
arch was cut into three sections of approximately 3 mm in length, proximal, medial and
distal to the heart. Each tissue section was placed between two foam pads in a plastic
embedding cassette and dehydrated and infiltrated overnight in the Citadel 2000
(Shandon) carousel style automatic tissue processor. Heat and vacuum were not utilized
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in the tissue processing. The clearing agent used was Histoclear II (National Diagnostics,
Atlanta, GA) and the paraffin used for impregnations was Paraplast Plus (Fisher
Scientific). The embedded tissue cassettes were kept refrigerated for future sectioning.
This procedure was repeated at week 20 on the remaining seven hamsters from groups N
and L, five hamsters from group L+G, and eight hamsters from group G. In addition,
plasma samples were taken from five hamsters in the N, G and L groups and four
hamsters in the L+G group at 20 weeks for lipid hydroperoxide analysis.

Lipid

hydroperoxides were extracted that same day and the extracted samples frozen at - 80° C.
At two weeks and ten weeks after STZ injection blood glucose levels were
evaluated using the FastTake glucometer. Hamsters with fasting blood glucose levels
greater than 200 mg/dL at two weeks after injection (WAI) and greater than 290 mg/dL at
10 WAI were considered hyperglycemic. Two hundred and ninety mg/dL of glucose
represented a 62% increase in fasting glucose values over the non-treated hamsters
average glucose values at week 10. In humans, only a 26% increase in fasting glucose
values on more than one occasion is indicative of diabetes, therefore, the criteria used for
the hamsters in this study was fairly strict. Since the hamsters glucose values varied by
±30 mg/dL, this strict criteria assured that the glucose values between the non-treated
hamsters and the glycemic hamsters were significantly different at the p<0.001 level.
Four STZ injected hamsters did not meet the criteria and were eliminated from the study.

Lipid Analysis
Plasma aliquots for lipid analysis were thawed at room temperature (RT), diluted
1:2 with physiological saline solution (The Butler Company, Columbus, OH), and briefly

54

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

vortexed.

Total cholesterol (TC) levels were determined by a cholesterol oxidase

enzymatic method (INFINITY ™ Cholesterol Reagent procedure No. 402, Sigma
Diagnostics, St. Louis, MO). Samples with TC beyond the assay range of linearity (750
mg/dL) were further diluted with physiological saline to a final dilution of 1:8 and re
assayed. Results were then multiplied by the dilution factors. High density lipoprotein
cholesterol (HDL-C) levels were determined by precipitation of both low density
lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C)
with phosphotungstic acid in conjunction with magnesium chloride (HDL Cholesterol
Reagent (PTA/MgCb) procedure No. 352-4, Sigma Diagnostics, St. Louis, MO). The
cholesterol concentration in the remaining HDL fraction was then assayed by the same
enzymatic method used to determine TC. The combined cholesterol in the VLDL and
LDL fractions (non-HDL-C) was calculated as the difference between TC and HDL.
LDL-C could not be calculated by the Friedwald method as triglycerides in the L and
L+G groups often exceeded 400 mg/dL. This increased level of triglycerides interferes
with the accuracy of the Friedwald calculation. Triglyceride levels were determined by
an enzymatic method (INFINITY ™ Triglycerides Reagent procedure No. 344, Sigma
Diagnostics, St. Louis, MO).

Samples with triglycerides beyond the assay range of

linearity (800 mg/dL) were further diluted with physiological saline to a final dilution of
1:10 and re-assayed.

Results were multiplied by the dilution factors and quantified

spectrophotometrically (Spectronic Genesys 5, Milton Roy Company, Rochester, NY).

Glucose Analysis
Serum aliquots for glucose analysis were thawed at RT and briefly vortexed.
Glucose levels were determined by a hexokinase enzymatic method (Glucose (Trinder)
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Reagent procedure No. 315, Sigma Diagnostics, St. Louis, MO). Since turbid samples
may give falsely high values a sample blank was used with all turbid samples according
to the recommended sample blank procedure. The sample blank was prepared by adding
the sample to physiologic saline and the absorbance of the sample blank was subtracted
from the absorbance of the sample assayed with the glucose reagent in order to obtain the
actual glucose concentration. Results were quantified spectrophotometrically (Spectronic
Genesys 5, Milton Roy Company, Rochester, NY).

Lipid Hydroperoxide (LPO) Analysis
Extracted plasma samples from week 20 for LPO analysis were thawed on ice.
Quantification of lipid peroxidation was determined using a Lipid Hydroperoxide Assay
Kit (Cayman Chemical Co., Ann Arbor, MI) that measures the hydroperoxides directly
by utilizing redox reactions with ferrous ions. Hydroperoxides are highly unstable and
react readily with ferrous ions to produce ferric ions.
detected using thiocyanate ion as the chromogen.

The resulting ferric ions were
Results were quantified on a

spectrophotometric plate reader (ELX800, Bio-Tek Instruments, Inc., Winooski, VT) at
490 nm.

Insulin Analysis
Plasma samples for insulin analysis were thawed at RT. Quantification of insulin
was determined using a rat insulin radioimmunoassay (RIA) kit (Linco Research Inc., St.
•

•

•

•

•

•

Charles, MI) utilizing insulin labeled with

1

•

Iodine and a rat insulin antiserum raised in

guinea pigs to determine the level of insulin by a double antibody/PEG technique.
According to the manufacturer this antibody has been shown to have 100% specificity for
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hamster insulin. After performing the assay, remaining radioactive counts per minute
were determined (LKB WALLAC 1282 Compugamma Universal Gamma Counter,
Gaithersburg, MD) and a standard curve was plotted using nonlinear regression. Insulin
levels in ng/mL were determined.

Statistical Analysis
Student’s /-test with a two-tailed measurement of P values was used to compare each
group’s lipid, glucose, LPO, and insulin values between the 10 week timepoint and the 20
week timepoint. One-way factorial analysis of variance (ANOVA) followed by Tukey’s
Multiple Comparison post test was used to compare each group’s lipid, glucose, LPO,
and insulin values within each timepoint.

All analysis was done using the V2.0b

GraphPad Prism (GraphPad Software, Inc) statistical program. Data was expressed as
mean ± SD. Values of P < 0.05 were considered statistically significant. If the F test
was significant, differences between subsets were performed on logarithmically
transformed data. For correlation data, Spearman correlation coefficients were calculated
on logarithmically transformed data.

Immunohistochemical Analysis
Immunohistochemical (IHC) analysis was performed on formalin fixed, paraffin
embedded sections cut at 5pm and mounted on Superfrost Plus™ slides. Subsequently
the paraffin was removed by placing slides in two 10 minute baths of toluene followed by
rehydration of the tissue sections via 6 minute baths in 100% EtOH, 95% EtOH, ddFEO
and final submersion in PBS.
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Slides containing sections of pancreas from hamster groups N, L, and G were first
incubated for 5 minutes in 3% H2 O2 in water to quench endogenous peroxidase activity
and then rinsed in PBS for 5 minutes.

All incubations took place in a humidified

chamber. Sections were then blocked with dilute goat serum contained in the
VECTASTAIN® Elite® ABC Peroxidase Kit (Vector Laboratories, Inc., Burlingame,
CA) and incubated at room temperature for 20 minutes. Excess serum was blotted from
the sections. The sections were then incubated overnight at 4 0 C with a rabbit IgG
polyclonal primary antibody to porcine insulin (ICN Pharmaceuticals, Inc., Aurora, Ohio)
diluted with PBS containing 0.1% immunohistochemical grade bovine serum albumin to
prevent adsorption of the antibody to the plastic microfuge tube in which the final
dilution was made. This antibody is known to react with cytoplasmic and extracellular
insulin in humans, pigs and rats. After rinsing in PBS for 5 minutes a biotinylated goat
anti-rabbit IgG secondary antibody was added.

This introduced biotin into the section at

the location of the primary insulin antibody. After rinsing in PBS for 5 minutes an
avidin:biotinylated peroxidase enzyme complex (ABC) was added. This bound to the
biotinylated secondary antibody. Sections were again rinsed in PBS for 5 minutes and
then Vector® VIP peroxidase substrate solution was added until the desired purple stain
intensity developed.

The section were rinsed in tap water and counterstained with

Vector® Blue, cleared and mounted.
IHC analysis was similarly performed on slides containing sections of the aortic
arch from hamster groups N, L, G, and L+G using an affinity-purified goat polyclonal
antibody, ox-LDL receptor-1 (also designated LOX-1) diluted 1:10 with PBS with 1%
bovine serum albumin. This antibody was raised against a peptide within an internal
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region of ox-LDL receptor-1 of mouse origin (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) and previously had been demonstrated to react with mouse and rat tissue.

A

Yectastain® ABC Alkaline Phosphatase enzyme kit was used containing a biotinylated
anti-goat IgG secondary antibody make in rabbit.

The substrate used was Fast Red

(Signet Labs, Inc., Dedham, MA) and the counterstain used was Hematoxylin QS (Vector
Laboratories, Inc., Burlingame, CA).
Following the same protocol IHC analysis was performed on hamster aortic
sections using a rabbit anti-MDA antibody (Alpha Diagnostic International, San Antonio,
TX) in which the MDA was coupled with keyhole limpet hemacyanin (KLH) prior to
injection into rabbits. This antibody was also known to react with mouse and rat tissue.
Serial sections were used for all IHC protocols and run simultaneously applying
1% bovine serum albumin in PBS in place of the primary antibody.

Peptide

neutralization was also performed using the peptide that the LOX-1 antibody was raised
against (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The peptide was reconstituted
in PBS to a concentration of between 0.2 - 1 mg/mL. Antibody at the same 1:10 dilution
as used in the IHC protocol was combined with a ten-fold excess of peptide and
incubated for 2 hours at RT. The antibody-peptide complexes were centrifuged at full
speed in a microfuge for 15 minutes before use. During the IHC protocol the supernatant
antibody-peptide complexes were applied to duplicate sections in place of the LOX-1
antibody.

Photodocumentation
Representative sections from each group were examined using the 20X objective
on an Olympus BHS-RFC microscope (Olympus America, Inc., Lake Success, NY).
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Images were captured using a Qlmaging CCD MicroPublisher digital camera and
QCapture software (Qlmaging, BC, Canada).
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CHAPTER VI

RESULTS

Body Weights
The average initial hamster weight of for all hamsters was 95.79 grams. The
average weight increased steadily through 8 weeks of treatment to 106.5 grams.
Hamsters sacrificed at week 10 had an average weight of 103.9 grams and hamsters
terminated at week 20 had an average weight of 106.7 grams. There was no significant
difference in the average weight of the 4 groups at the start of the study. There were also
no significant differences in the initial weights within each group between hamsters at
week 10 and hamsters at week 20.
Group Differences. At the 10 week timepoint the hyperlipidemic/normoglycemic (L)
hamsters

had

significantly

higher

(p<0.05)

body

weights

than

the

normolipidemic/normoglycemic (N) hamsters. While the mean weight of each group at
the 10 week timepoint had increased over the mean initial body weight only the
hyperlipidemic/normoglycemic (L) hamsters significantly increased their weight
(p<0.001). There were no other significant differences between the groups at the 10
week time point. At the 20 week timepoint there were no significant differences in body
weights between groups.
Timepoint Differences. While the average body weight of each group at 20 weeks had
increased over the average initial weight only the normolipidemic/normoglycemic (N)
hamsters body weight increased significantly (p < 0.01). Between the 10 week timepoint
and the 20 week timepoint the average weight of the normolipidemic/normoglycemic
(N), normolipidemic/glycemic (G) and hyperlipidemic/hyperglycemic (L+G) groups was
higher at week 20 while the average weight of the hyperlipidemic/normoglycemic (L)
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group was lower at week 20. However, there were no significant differences within each
group at the week 10 timepoint versus the week 20 timepoint (Table 1).

Lipid Analysis
Group Differences. Comparisons between the four groups, at the 10 week timepoint and
the 20 week timepoint produced the following results:
Total Cholesterol and non-HDL-C. The L group had significantly higher TC and nonHDL-C than the N or G groups at both week 10 (p < 0.001) and week 20 (p < 0.001).
The L+G group had significantly higher TC and non-HDL-C than any other group at both
week 10 (p < 0.001) and week 20 (p < 0.001). There was no significant difference in TC
and non-HDL-C between the N group and the G group at either the 10 week or 20 week
timepoint (Tables 2, 3, & 4, Graphs 1 & 2).
HDL-C. The L group had significantly higher HDL-C than the N or G group at both
week 10 (p < 0.05) and week 20 (p< 0.001). The L+G group had significantly higher
HDL-C than any other group at both weeks 10 (p < 0.001) and 20 (p < 0.001). At week
10 there was no significant difference in HDL-C between the N and G groups but at week
20 HDL-C in the G group was decreased significantly compared to the N group (p <
0.01) (Tables 2, 3, & 4, Graph 3).
Triglycerides (TGI. The L and G groups had significantly higher triglycerides than the N
groups at both week 10 (p < 0.001) and 20 (p < 0.05). The L+G group had significantly
higher triglycerides than any other group at both week 10 (p < 0.001) and 20 (p < 0.001).
There was no significant difference in the triglycerides between the L and G group at
these timepoints (Tables 2, 3, & 4, Graph 4).
TC/HDL-C. The L group had a significantly higher TC/HDL-C ratio value than the N
group at both weeks 10 (p < 0.001) and 20 (p < 0.01) and a significantly higher ratio
value than the G group at weeks 10 (p < 0.001) and 20 (p < 0.05). The L+G group had a
significantly higher TC-HDL-C ratio than the N and G groups at week 10 (p < 0.001) and
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week 20 (p < 0.001) and significantly higher than the L group at week 10 (p < 0.001) and
week 20 (p < 0.05). There was no significant difference in the TC-HDL-C ratio between
the N and G groups at either time (Tables 2, 3, & 4, Graph 5).
TG/HDL-C. At the 10 week timepoint the L group had almost a 3-fold increase in the
average TG/HDL-C ratio over the N group. The G group had almost a 5-fold increase in
the average TG/HDL-C ratio over the N group at the week 10 timepoint. Also at the
week 10 timepoint the L+G group had a 34.5-fold increase in the average TG/HDL-C
ratio over the N group, which was also a 7-fold increase over the G group and almost a
12-fold increase over the L group. At the 20 week timepoint the L group had a 1.7-fold
increase in the average TG/HDL-C ratio over the N group. The G group had a 3-fold
increase in the average TG/HDL-C ratio over the N group at the 20 week timepoint. Also
at the 20 week timepoint the L+G group had a 10-fold increase in the average TG/HDL-C
ratio over the N group, a 3.5-fold increase over the G group and a 5.8-fold increase over
the L group (Table 2, Graph 6).
Timepoint Differences. Comparisons within the four groups, between the two time
points showed that the only significant differences within the groups when comparing the
lipid levels of hamsters at week 10 versus those at week 20 occurred in the N group. At
the 20 week timepoint the TC, non-HDL-C, and TC/HDL-C in the N group were
significantly higher (p < 0.05) than at the 10 week timepoint and the triglycerides in the
N group were significantly higher (p < 0.01) at the 20 week timepoint than at the 10 week
tiempoint (Table 2, Graphs 1, 2, 3, 4, 5, & 6).

Glucose Analyses
Group Differences.

Comparisons between the four groups at the two time points

showed that the L+G and G groups had significantly higher glucose levels than the N
group at both weeks 10 (p < 0.001) and 20 (p < 0.001). The L+G and G groups also had
significantly higher glucose levels than the L group at weeks 10 (p < 0.01) and 20 (p <
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0.001 and p < 0.05 respectively).

At week 10 the L group had significantly higher (p <

0.01) glucose levels than the N group but at week 20 there was no significant difference
in glucose between the N and L groups.

There was no significant difference in the

glucose levels between the G and L+G group at either time (Tables 2, 3, & 4, Graph 7).
Timepoint Differences. There were no significant differences in glucose values of the N
group between weeks 10 and 20, the G group between weeks 10 and 20, the L group
between weeks 10 and 20, or the L+G group between weeks 10 and 20 (Table 2, Graph
7).
Insulin Analyses
At week 10 the L+G and the G groups had significantly increased insulin levels
over the N group (p<0.001). The L group also had significantly increased insulin over
the N group (p<0.05). The L+G group had significantly increased insulin over the L and
the G groups (p<0.001). There was no significant difference in insulin between the G
and L groups.
At week 20 the L+G group had significantly increased insulin levels over the N
group (p<0.001). Although the L and G groups still had glucose values higher than the N
group at week 20 it was no longer significant due to an increase in the insulin levels in
the N group from week 10 to week 20. The L+G group still had significantly increased
insulin over the L and G groups (p<0.001). The G group at this time had significantly
elevated insulin over the L group (p<0.05) at the 20 week timepoint due to an increase in
insulin levels in the G group and a decrease in insulin levels in the L group from the 10
week values (Tables 2, 3, & 4, Graph 8).

Lipid Hydroperoxide (LPO) Analysis
At the 20 week timepoint mean LPO values (uM) for each group were as follows:
5.13 in the N group, 2.81 in the G group, 5.24 in the L group and 7.80 in the L+G group.
The L+G group had significantly higher (p < 0.01) LPO values than the G group. There
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were no other significant differences between groups (Graph 1). Correlation between the
log of total cholesterol and the log of lipid hydroperoxides in N, G, L and L +G hamsters
at 20 weeks had an r value of 0.5033 and a p value of 0.0237 (Graphs 9 & 10).

Pancreatic Islet Histopathology
At the 10 week timepoint the islets in the pancreata of the L group are slightly
smaller and there were fewer islets than in the pancreata of the N group. In addition the
beta cells in the L group appeared less dense and vacuolated when compared to the beta
cells in the pancreas of the N hamsters. The islets in the pancreata of the G group at the
10 week timepoint were even smaller and fewer and the beta cells even more vacuolated
than those of the L group (Figures 2 & 3).

Pancreatic Islet Immunohistochemistry
In the N group, cells immunoreactive for insulin designated by the dark purple
stain are distributed throughout the islets. Insulin immuno-reactivity is greatly decreased
in the islets of the age matched L group. Even though the islets in the G group were
smaller and more vacuolated than the N and L group the immuno-reactivity appears to be
similar to that of the L group (Figures 2 & 3).

Aortic Arch Lesion Development
At 20 weeks there was no visible atherosclerotic lesion development in the N or G
groups. The L group had early stage, fatty streak lesions with foam cell formation. The
most striking lesion development occurred in the L+G group where intermediate stage,
fibro-muscular lesions included features of advanced stage, complicated lesions. These
lesions had visible SMC proliferation characteristic of the fibro-muscular stage of lesion
development. The core of these lesions was missing, having fallen out during sectioning.
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This indicates that the core most likely consisted of dead cells and gruel characteristic of
more advanced lesions (Figure 4).

Immunohistochemistry for M PA and LOX-1
M PA. There was very faint immuno-reactivity for MDA in the N group with a few focal
areas in the SMCs and possibly some EC immuno-reactivity. There was moderately
intense immuno-reactivity for MDA in the SMCs of the G group and visible EC immunoreactivity. The foam cells in the L group were highly immuno-reactive but the SMCs had
similar reactivity to the N group. The L+G group intense immuno-reactivity within the
core of the lesion, and in ECs and SMCs (Figure 5).
LOX-1.

The N group had immuno-reactivity for LOX-1 within the SMCs with a few

focal areas and the appearance of some EC immuno-reactivity. There was moderately
intense immuno-reactivty for LOX-1 in the SMCs of the G group and visible EC
immuno-reactivity. However, not only were the foam cells in the L group moderately to
intensely immuno-reactive but the SMCs were also highly immuno-reactive. The L+G
group was intensely immuno-reactive within the core of the lesion and also throughout
the SMCs (Figure 6 ).
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CHAPTER VI

DISCUSSION

Type I and Type II diabetics are prone to the same risk factors for developing
atherosclerosis as non-diabetics, however their risk is increased by a factor of 2 to 5. In
order to study the mechanism(s) responsible for this accelerated atherosclerosis in
diabetics development of a suitable animal model of diabetic atherosclerosis is necessary.
While genetic models of diabetes have been developed in rodents, and other animal
species may develop diabetes spontaneously, they are not good models of diabetic
atherosclerosis since they either do not develop lesions similar to humans or they have
lipid and lipoprotein metabolism and profiles that are different from humans.

One

method that has been determined to be useful is to take an animal that is a good model for
human atherosclerosis and superimpose diabetes. Initially pancreatectomy was utilized
to simulate diabetes, however, without the administration of insulin these animals would
not live long enough to develop atherosclerosis. A second method, the administration of
diabetogenic agents that cause B-cell ablation such as STZ, has been used in animal
models. A diabetic state has previously been induced by STZ in the APA strain of the
Syrian hamster extensively used in Japan [296].

Objective 1
The first objective of this study was to determine whether one intraperitoneal
injection of 40 mg/kg body weight of STZ could induce a diabetic-like hyperglycemic
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state in the Syrian F|B hamster, an atherosclerotic hamster model used in the United
States, and whether the diabetic-like hyperglycemic state was similar to human Type I or
Type II diabetes.
Hyperglycemia is the primary clinical manifestation of both Type I and Type II
diabetes. The comparison of hamster fasting glucose values between the STZ injected
hamster groups (G and L+G) and the non-STZ injected hamster groups (N and L)
indicated that one intraperitoneal injection of 40 mg/kg body weight of STZ was
successful in creating a hyperglycemic state in the Syrian FiB hamster. The G and L+G
groups injected with STZ had significantly higher fasting plasma glucose levels than the
N and L groups, at both weeks 10 and 20. After STZ injection, the fasting plasma
glucose level of the STZ-treated groups (G and L+G) was 1.75 - 2.75 times higher than
those of the non-treated hamsters.

In similar studies with APA hamsters [288] non

fasting serum glucose levels of STZ treated hamsters were 2 - 3 times as high as those of
control animals.

These results indicate that a single injection of STZ caused

hyperglycemia similar to that found in human diabetes in the absence of insulin
administration.
Of interest was that the L group also had significantly elevated glucose levels
over the N group at week 10 but not at week 20. This lack of significant difference at
week 20 was due to an elevation in the fasting glucose levels of the N group at 20 week
and not to a decrease in glucose values in the L group.

Elevated glucose in

hyperlipidemic hamsters was also previously demonstrated in studies of the APA hamster
strain [280].
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In addition to hyperglycemia, another characteristic of human diabetes is
dyslipidemia characterized by hypertriglyceridemia, decreased plasma HDL, and
increased small, dense LDL particles, the so-called “atherogenic lipid triad” [297-299],
However human diabetics may not necessarily have an increase in total cholesterol or
LDL-C concentrations.

In this study there was no significant difference in total

cholesterol between the N and G groups. This differs from what was seen previously by
Simionescu et al. [280] in the APA strain of the Syrian hamster where higher total
cholesterol in the STZ treated hamsters was observed. There was also no significant
difference in non-HDL-C cholesterol between the N and G groups.

This lack of

significant increase in both total cholesterol and non-HDL-C in the F]B STZ treated
hamsters is similar to what is seen in human diabetes.
The G group also had approximately a 4.6-fold increase in triglycerides over the
N group at the 10 week timepoint but only a 2.1-fold increase at the 20 week timepoint.
This was due more to an increase in triglycerides in the N group as they aged as opposed
to a decrease in the triglycerides in the G group. Ebara et al. [300] also observed
increases in the triglycerides of STZ treated APA hamsters by 5.6-7.8-fold over normal
hamsters just 10 days after STZ injection. The striking elevation in plasma triglycerides
seen in the STZ treated FiB hamster is similar to what is observed in human diabetes.
At 10 weeks there was also no significant difference between the HDL-C levels of
the N and G groups. However by 20 weeks the G group had significantly decreased
HDL-C from the N group. This was also previously seen in STZ treated APA hamsters
[296]. Again, this decrease in HDL-C is similar to what has been reported in human
diabetes.
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While there may be no increase in absolute non-HDL-C fraction which would
contain LDL in the G group, increases noted in the TG/HDL ratio over the N group
indicates the presence of larger amounts of small, dense LDL in the G group. At week 10
the G group had approximately a 5-fold increase in this ratio over the N group and at 20
weeks approximately a 3-fold increase over the N group. This increase in small, dense
LDL is similar to what is seen in human diabetics. In this study, the STZ treated Syrian
FiB hamster exhibited not only the hyperglycemia similar to that seen in non-treated
human diabetics but also a similar lipid profile to that prevalent in human diabetes,
making it a relevant model of human diabetes.
Determining whether STZ injection resulted in a model with characteristics
similar to human Type I or Type II diabetes was more complicated. In humans, Type I
diabetics have an absence of insulin production and Type II diabetics are characterized by
an initial increase in insulin production in an attempt to compensate for a decreased
peripheral sensitivity to the insulin. This initial increase in insulin is followed by a slow
decline in insulin levels with the Type II diabetic eventually becoming hypoinsulinemic
and hyperglycemic. It was anticipated in this study that STZ injection would destroy the
beta cells. If all the beta cells were destroyed then no insulin would be produced. Under
these circumstances the hamsters would not have survived without the administration of
exogenous insulin. One of the reasons it had previously been determined that hamsters
could survive for a relatively long time after STZ treatment without the administration of
exogenous insulin was because of their continued secretion of insulin at a high enough
level to allow enough glucose to enter into the cells of the body [301]. In this study the
STZ treated hamsters not only continued to secrete insulin but had statistically significant
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increased insulin levels over the N group at both weeks 10 and 20 and over the L group
by week 20. The plasma insulin levels indicated a hypersecretory state similar to that
which occurs initially in human Type II diabetes.
In order to determine whether the beta cells of the STZ injected hamsters were
still producing insulin, sections of pancreata were reacted with an anti-insulin antibody
and visualized with chromagen. While the beta cells themselves appeared vacuolated and
the size of the islets smaller than the non-treated hamsters the immunoreactivity for
insulin was evident in islet remnants. The lack of dependence on insulin, and its apparent
continued secretion from the beta cells in the STZ treated Syrian FiB hamsters appeared
to be more reflective of type II diabetes rather than type I diabetes. It has been suggested
by others that the L+G hamster manifests the conditions of both insulin resistance and
insulin impairment [302] as seen in human type II diabetes.

Objective 2
The second objective of this study was to compare the development of
atherosclerotic

lesions

between

normal

non-treated

(N),

hyperglycemic

(G),

hyperlipidemic (L) and combined hyperlipidemic/hyperglycemic (L+G) hamsters.
During the course of this study neither the N (Figure 1A) nor the G group (Figure
IB) developed atherosclerotic lesions. The L group (Figure 1C) developed early fatty
streak lesions characterized by foam cell accumulation. The most striking findings were
the extremely more advanced fibro-muscular lesions observed in the L+G group (Figure
ID).

These fully developed intermediate stage lesions included SMC proliferation

characteristic of the fibro-muscular stage of lesion development. In addition, the SMCs
migrated to form a cap over a large vacant core. While this core was pulled out during
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sectioning it most likely consisted of dead cells and extracellular matrix. This core is
characteristic of more advanced lesions.

Obiective 3
The third objective of this study was to determine whether any of the following
factors influenced atherosclerotic lesion development in any of the four groups: glucose,
triglycerides, total cholesterol, Non-HDL-C, HDL-C, TC/HDL-C ratio, TG/HDL-C ratio
as an indicator of small dense LDL production, lipid hydroperoxides in the plasma, and
MDA and LOX-1 in the vascular wall of the hamster aortic arch.
The L+G group had significantly greater lesion development than all other
groups. The L+G group had fully developed fibro-fatty lesions by 20 weeks while the G
group had no lesion development. In relation to the L+G group the L group had less
advanced fatty or early streak lesions. In order to focus on what might have influenced
this apparent accelerated atherosclerotic lesion development in the L+G group, plasma
glucose, insulin, lipids, and lipid hydroperoxides were measured and staining for MDA
and LOX-1 in the aortic arch was performed. It is important to note that at 20 weeks
there were no significant differences in the weights between groups (Table 1). This
eliminated weight as a confounding factor in any of the studies findings.
Glucose. The view that many of the pathologic effects of diabetes are from the condition
of hyperglycemia itself is widely held. However, it should be noted that increased lesion
development is already noted upon diagnosis of diabetes indicating that these lesions are
most likely developing during the euglycemic pre-diabetic state.
Hyperglycemia, unique to patients with diabetes and impaired glucose tolerance,
has been examined as a potential atherogenic factor. Hyperglycemia has been shown to

72

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

increase glycation of proteins and nucleic acids and favor oxidative reactions in the
microenvironment of the artery wall [303] leading to the speculation that the origin of
diabetic vascular complications is the formation of AGEs and oxidative stress. Actually
it is very difficult to separate these two mechanisms. Because the production of many of
the AGEs involves oxidation and glycation the term glycoxidation is often used when
referring to this process in diabetics. AGES are therefore glycated proteins, lipids, or
nucleic acids that have been oxidatively modified or glycoxidized due to hyperglycemia
and the increased oxidative stress caused by the hyperglycemia [304], Proteins may be
further damaged by hydroxyl radicals released during glucose auto-oxidation.

High

glucose levels have also been shown to stimulate ROS through the PKC-dependent
activation of NADPH oxidase and to stimulate mitochondrial superoxide production
further increasing the oxidative stress in diabetics [305, 306]. Diabetes may increase
mitochondrial generation of ROS through some diabetes associated mitochondrial
dysfunction. In addition elevated glucose has been shown to increase the expression and
activity of 12-lipoxygenase in SMCs.
AGEs form in LDL primarily by glycosylation of its phospholipids [307] but
there is also the potential of glycosylation of the apoprotein B-100 molecule [308].
Increased glycated LDL has been demonstrated in the circulation and the vascular wall of
diabetics and has been shown to be very sensitive to oxidation [309, 310]. It has been
suggested that glycoxidized LDL is more rapidly taken up by macrophages than just
oxidized LDL [311]. This modification of lipoproteins could therefore be one of the
mechanisms for the early development of atherosclerosis in diabetics.
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RAGE, the receptor for AGE, is also increased in diabetes. The binding of AGE
to RAGE increases oxidative stress and activation of the inflammatory response in the
vasculature. AGE-RAGE interaction causes activation of NF-kB. This system is subject
to a positive feedback loop in that the binding of RAGE by AGEs leads to the
upregulation of more RAGE through this NF-AB dependent mechanism. When
endothelial cell RAGE binds AGE, NF-&B translocation to the nucleus activates the gene
expression of VCAM-1 [312, 313]. The increased expression of adhesion molecules in
diabetics may further contribute to accelerated atherogenesis [314, 315].
In this study, the fasting plasma glucose values between the G group and the L+G
group were not statistically different indicating that any differences in lesion
development between these two groups was not due to a direct effect of glucose alone.
Elevated glucose in hyperlipidemia has also been previously demonstrated in studies of
the APA hamster strain [280]. It appears that glucose alone may not be a factor in the
accelerated development of atherosclerosis in the L+G group.
Total Cholesterol, HDL-C, Non-HDL-C, and TC/HDL-C ratio.

There was no

statistical difference between the G group and the N group with regards to TC, HDL-C,
non-HDL-C and TC/HDL-C ratio the week 10 timepoint. A higher TC/HDL ratio is
generally indicative of a more proatherogenic lipid profile. At week 20 the only
significant change was that the glycemic hamsters now had significantly lower levels of
HDL-C than the non-treated hamsters.

HDL-C is responsible for the removal of

cholesterol from the tissues. Type II diabetics often have low HDL-C levels which may
be partly responsible for the increased risk of atherosclerosis in diabetics [316], However
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the decrease in HDL-C levels was not enough to cause a significant change in the
TC/HDL-C ratio.
In contrast to the G group, the L+G group had significantly higher total
cholesterol, HDL-C, Non-HDL-C and TC/HDL-C ratios compared to the other three
groups. The G group had no visible lesion development whereas the L+G group had
more advance atherosclerosis compared to the L group.

These results indicated that

increased plasma lipoprotein levels may be responsible for the accelerated atherosclerosis
in the L+G group and that the TC/HDL-C ratio may indeed be an accurate indicator of
the development of atherosclerosis in the Syrian FjB hamsters.
Triglycerides. The hypertriglyceridemia seen in the G and L+G groups could be due to
either the increased production of VLDL and chylomicrons, their decreased clearance, or
both.

A previous study determined that the hypertriglyceridemia seen in diabetic

hamsters was not due to a difference in the amount of food consumed and that the hepatic
output of triglycerides was actually decreased in diabetic hamsters.

The study also

determined that the increase in triglycerides was associated with a catabolic defect of
VLDL triglyceride [300] not an increase in the production of VLDL. In addition to a
decrease in the catabolism of VLDL triglycerides, chylomicron accumulation in the
plasma due to impaired clearance could also be a contributing factor to the increased
concentration of triglyceride-rich lipoproteins in the diabetic hamster.
In a previous study, diabetic hamsters demonstrated reduced lipoprotein lipase
(LPL) activity by about one half and this deficiency in LPL activity was associated with
an increase in susceptibility to atherosclerosis in the FiB hamster [245],

LPL is a

glycoprotein synthesized and secreted by macrophages and other cells [317].

This
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enzyme adheres to the luminal side of vascular endothelial cells and hydrolyzes
triglycerides in chylomicrons and VLDL thereby converting these to denser lipoproteins
such as chylomicron remnants, intermediate density lipoprotein (IDL) and LDL. LPLs
effect on the development of atherosclerosis is uncertain. Recent studies have revealed
that LPL on macrophages and in the plasma may have different roles with different
effects on the development of atherosclerosis [84], Highly oxidized but not native or
mildly oxidized LDL downregulates LPL production by macrophages [318].

Several

studies have provided evidence that LPL secreted by macrophages promotes foam cell
formation and accelerates atherosclerosis [319, 320].
Increased fasting triglyceride levels are characteristic of human diabetes. There is
mounting evidence that elevated triglycerides in diabetics constitute a risk factor for
atherosclerosis.

Several studies have demonstrated that high levels of triglyceride rich

lipoproteins and delayed remnant removal may increase monocyte adherence to
endothelial cells inducing atherogenesis [321, 322], In patients with hypertriglyceridemia,
serum levels of soluble E-selectin, ICAM-1 and VCAM-1 were shown to be elevated
independently of other risk factors [323, 324],

There is also some evidence that

triglyceride-rich lipoproteins readily cross the endothelial cell barrier [134, 325],
All three treated groups of hamsters (G, L, and L+G) had significantly increased
triglycerides over the non treated hamsters. The L and G groups had approximately a 4 5-fold increase at the 10 week timepoint but only a 2 - 3-fold increase at the 20 week
timepoint. This was due to an increase in triglycerides in the N group at 20 weeks as
opposed to a decrease in the triglycerides in the G and L groups. Ebara et al. [300] also
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observed increases in the triglycerides of STZ treated hamsters by 5.6 - 7.8-fold over
normal hamsters just 10 days after STZ injection.
There was an even greater increase in the triglycerides of the L+G group. Their
triglycerides were increased 150-fold over the N group at 10 weeks but were increased
only 66.5-fold over the N group at 20 weeks. The triglycerides in the L+G group were
also increased 34-fold over the L and the G groups at 10 weeks and approximately 28fold at 20 weeks indicating that the combination of hyperglycemia and hyperlipidemia
had a synergistic effect on the level of triglycerides.
It has been observed that elevated plasma glucose often produces similar
triglyceride levels to high saturated fat diets in humans but with substantially lower
serum LDL cholesterol concentrations [326].

Indeed in this study there was no

significant difference between the triglycerides in the L and the G groups. Since the L
group developed foam cell lesions but the G group had no lesion development,
triglycerides alone are probably not responsible for the lesion development in the L
group. The difference between the G group and the L+G hamsters seems to be in the
lipoprotein fractions. Therefore there may be a critical level of LDL-C below which
triglyceride-rich lipoproteins do not increase the risk of atherosclerosis.
Lipolytic products of triglyceride-rich lipoproteins, such as free fatty acids
(FFAs), have also been shown to increase the permeability of endothelial monolayers,
enhance lipid accumulation in SMCs, promote endothelial production of inflammatory
mediators (NF-&B, IL-8, ICAM-1), and alter the extracellular matrix synthesis in cultured
SMCs. Studies with both endothelial cells [305] and SMCs [327] have demonstrated that
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increased fatty acids also increased oxidative stress and can increase NF-&B activation
and the expression of NF-£B mediated genes including VCAM-1.
Fatty liver, which was evident in both the L and the L + G groups, are linked to
insulin resistance. As a result of insulin resistance, there is an excess release of free fatty
acids (FFAs) into the circulation leading to more FFA delivery to the liver. The liver
converts the increased FFAs to TG which it then incorporates into an increased number
of VLDL particles. That free fatty acids could also cause insulin resistance was first
proposed by Randle et al., in 1963 [328]. In fact it was more recently determined that
insulin resistance is more important than triglyceride levels in causing endothelial
dysfunction since hypertriglyceridemia in the absence of severe insulin resistance does
not appear to cause endothelial dysfunction [329],
Insulin resistance could also be a factor in the accelerated lesion development of
the L+G group.

At the 20 week timepoint there was no difference in insulin levels

between the G group and the N group or between the L group and the N group.
However, the L+G group had significantly elevated insulin over all 3 of these groups.
Our findings suggest that the combination of hyperglycemia, insulin resistance, and the
increased fatty acids seen in the hyperglycemic/hyperlipidemic FiB hamster may
contribute to endothelial dysfunction and increased atherosclerosis. Moreover, this effect
may be considered additive or synergistic.
Plasma Lipid Hydroperoxides. Increased plasma lipid peroxidation products have been
observed in both Type I and Type II human diabetics [330, 331], Previous studies have
demonstrated increased levels of plasma peroxides in the combined hyperlipidemic,
hyperglycemic hamsters of the APA strain, sometimes almost double the normal
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concentration [280, 295, 332]. In this study the L+G group had significantly elevated
lipid hydroperoxides over the three other groups. The G group did not have elevated
lipid hydroperoxides and this could serve as another difference between the G and L+G
groups that may be contributing to the accelerated atherosclerosis seen only in the L+G
group.
TG/HDL ratio. The LDL levels of diabetics are often similar to non-diabetics but the
LDL that they have are denser and have a higher affinity for proteoglycans ex vivo [175,
176]. Epidemiologic studies have demonstrated that small, dense LDL particles are
associated with a greater risk of atherosclerosis [333-336].
In this study there was no significant increase in the absolute non-HDL-C fraction
containing VLDL and LDL between the N and G groups, however, differences in the
TG/HDL ratio between these two groups indicate a potential difference in small, dense
LDL. Small, dense LDL particles more easily infiltrate the subendothelial space where
they aggregate and oxidize more readily than larger LDL particles. At 10 weeks the L
group had an almost 3-fold increase in this ratio over the N group indicating that
hyperlipidemia alone increased the level of small, dense LDL. The G group had almost a
5-fold increase in this ratio over the N group at the 10 week timepoint indicating that
hyperglycemia alone also increases the level of small, dense LDL. When combining
hyperlipidemia and hyperglycemia, as in the L+G group, this ratio was increased 34.5fold over the N group at 10 weeks indicating that the combination of hyperlipidemia and
hyperglycemia had a synergistic effect in increasing small, dense LDL. At 20 weeks the
L group had a 1.7-fold increase, the G group a 3-fold increase and the L+G group a 10fold increase in the TG/HDL-C ratio over the N group. This confirms that while the G
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group had an increase in small, dense LDL particles the higher levels of cholesterol seen
in the L+G group further increased the amount of small, dense LDL particles possibly
contributing to the accelerated atherosclerosis seen in the L+G group.
MDA and LOX-1 in the aortic arch. In this study the presence of immunoreactivity for
MDA and LOX-1 in the aortic arch of the hamsters were utilized as indicators of in situ
oxidation. The oxidative modification of lipoproteins could be one of the mechanisms
for the early development of atherosclerosis in diabetics. Diabetic patients have been
generally described as being under enhanced oxidative stress [337] as indicated by their
decreased plasma levels of vitamin E and C [338], and their increased serum MDA [172],
and urinary F2 -isoprostane [173]. This assertion is also supported by the presence of
elevated levels of auto-antibodies to ox-LDL in type II diabetics [174].
The source of free radicals in diabetes is not completely understood. Endothelial
cells may increase production of superoxide when exposed to glucose [339-341].
Glycated proteins are also known to lead to free radical formation causing oxidative
stress by releasing superoxide [342] and hydrogen peroxide and activating macrophages
through RAGE [343],
Many animal studies have shown a correlation of lipid oxidation as measured in
blood, urine or vessel wall extracts with the development of atherosclerotic lesions [309],
MDA is a highly reactive dialdehyde produced as a byproduct of PUFA peroxidation and
arachindonic acid metabolism.

Initially lipid peroxides are formed when PUFAs are

attacked by free radicals. The free radicals abstract an electron from the PUFAs during
this process.

The peroxides react with neighboring PUFAs until they encounter an

electron donor such as alpha-tocopherol or other antioxidant.

This chain reaction of
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PUFAs can compromise cell membrane integrity and lead to cell death. In addition,
when reacted with metal ions, such as iron or copper, lipid peroxides may form toxic
aldehydes [344] such as MDA and 4-hydroxynonel (4-HNE). MDA has been found in
atherosclerotic plaques and may be a critical factor in the endothelial cell dysfunction
caused by FFAs [134],
In addition, aldehydes readily combine with functional groups on proteins,
lipoproteins and DNA. MDA may modify the apolipoprotein B-100 particle on LDL
which is normally recognized by the LDL receptor. In a previous study the LDL in
diabetic hamsters was demonstrated to be more susceptible to oxidation than the LDL in
non-diabetic hamsters [345]. The apoB-100 particle can also be modified via glycation in
the presence of high glucose concentrations [346]. Therefore a person with uncontrolled
hyperglycemia already has an increased risk for apoB modification and atherosclerosis
[347] which may further be exacerbated by the presence of elevated aldehydes.
In this study MDA was present in the SMCs and ECs of the G group but appears
localized to the foam cells of the L group.

These two groups have similar triglyceride

and insulin levels and small, dense LDL as indicated by the TG/HDL-C ratios. The L
group had significantly higher TC, non-HDL-C, HDL-C, and TC/HDL-C ratio and while
not significant higher levels of lipid hydroperoxides than the G group. While MDA in the
aortic arch was not quantitated there was increased plasma LDL levels in the L group that
could potentially be modified by MDA and consequently taken up by LOX-1 on ECs and
macrophages in a non-saturation dependent manner.
The acceleration of atherosclerosis in the L+G group could be due to further
modification of the apo-BlOO particle by glycation which may further induce LOX-1.
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The induction of LOX-1 is regulated by many factors involved in atherogenesis. One of
the major mechanisms by which LOX-1 upregulation might induce atherogenesis is
through its induction of endothelial dysfunction which may involve the activation of NFAB at the transcriptional level [348]. The upregulation of LOX-1 in diabetics may be
caused by their increase in fatty acids, particularly linoleic acid which is increased in
LDL subfractions in patients with Type II diabetes. Linoleic acid has been demonstrated
to increase LOX-1 expression in human aortic endothelial cells [349].

Remnant

lipoproteins, which are also increased in diabetics, have been demonstrated to increase
monocyte adhesion to human umbilical vein endothelial cells (HUVECS) through LOX-1
receptor-coupled NF-AB-dependent nuclear transcription.

NF-AB, when activated,

upregulates proinflammatory gene expression, such as adhesion molecules including
VC AM-1, ICAM-1, E-selectin and MCP-1 [3 50] and LOX-1 [3 51 ]. EC expression of Creactive protein (CRP), an acute inflammatory marker, may also enhance endothelial
LOX-1 expression and in doing so promote endothelial dysfunction [204]. TNF-a, a
mediator of the acute phase response in inflammation, also upregulates LOX-1
expression in SMCs in advanced atherosclerosis in a dose- and time-dependent manner
[352]. It has recently been demonstrated that oxLDL may up-regulate NF-AB to a certain
extent but higher concentrations of oxLDL may actually inhibit NF-AB activation [351].
In this study LOX-1 immunoreactivity was observed in foam cells and SMCs in
the G group. Increased immunohistochemical staining of MDA in the SMCs was also
evident and could therefore be responsible for the up-regulation of LOX-1 in the
glycemic hamster. While MDA is also expressed in the L group it is localized more to
the foam cells than the SMC. LOX-1 however is expressed not only in the foams cell but
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also in the SMCs of the L group.

This indicates that LOX-1 might be induced by

something other than oxLDL in the SMCs of the L group such as TNF-a.
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CHAPTER VII

CONCLUSIONS

Hyperglycemia induced LOX-1 and MDA in the Syrian FiB hamster.
Hyperlipidemia also induced the expression of LOX-1 and MDA. The combination of
hyperglycemia and hyperlipidemia may have increased the expression of both LOX-1
and MDA.

Quantitative analysis of LOX-1 would be important to determining whether

LOX-1 may be a potential target in the treatment and prevention of accelerated
atherosclerosis in diabetics. The L+G group also have significantly elevated plasma lipid
hydroperoxides over the G group and this could also have contributed to their accelerated
atherosclerosis. However, a previous hamster study demonstrated that decreasing plasma
lipid peroxides and cholesterol oxidation products had no effect on fatty streak lesion
formation [345] therefore accelerated atherosclerosis in this model may not be dependent
on the extent of LDL oxidation and oxidative stress.

It is therefore important to further

investigate the effects of LOX-1 on endothelial dysfunction in order to determine whether
this may be a mechanism by which LOX-1 might contribute to accelerated
atherosclerosis in diabetics.
It appears that the accelerated atherosclerosis seen in the L+G hamsters was
mainly associated with their increased TC and non-HDL-C and not the effects of elevated
glucose. In fact clinical trials have documented that reduction of LDL-C is associated
with a significant reduction in risk for atherosclerosis among diabetic persons while
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reduction of blood glucose levels has a relatively small effect on macrovascular
atherosclerosis [353].
A recent study concluded that diabetes is a strong predictor of severe but not of
mild or moderate progression of atherosclerosis in humans [354], Our findings suggest
that the L+G Syrian FiB hamster is a useful model for determining the mechanism(s)
involved in the development of accelerated atherosclerosis under the conditions of
hyperglycemia. The results of this study indicated that while hyperglycemia alone is
probably not a cause of atherosclerosis in the Syrian FiB hamster it may contribute to the
development of atherosclerosis when combined with elevated numbers of LDL particles
and small dense LDL particles [355]. Kondo et al., recently proposed that there may be a
critical size of small dense LDL-C (25.5 nm) above which triglyceride-rich lipoproteins
do not increase the risk of atherosclerosis and that there is a critical level of TG (1,500
mg/L) above which LDL is more susceptible to oxidation [356]. While the G group in
this study had an increase in small, dense LDL particles, the higher levels of cholesterol
and triglycerides seen in the L+G group further increased the amount of small, dense
LDL particles possibly contributing to the accelerated atherosclerosis seen in the L+G
group.

In addition, the TC/HDL-C ratio appeared to be an accurate indicator of the

development of atherosclerosis in the Syrian FiB hamsters since it was significantly
elevated in the L+G group but not in the G group.
The elevated insulin levels in the L+G group may also have contributed to their
accelerated atherosclerosis. Elevated insulin levels seen in the pre-diabetic phase of Type
II diabetes may also be a contributing factor to accelerated atherosclerosis in these
patients. Therefore treatment of type II diabetes may be best aimed at not only lowering
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LDL-C but elevating HDL, decreasing triglycerides and preventing the hyperinsulinemia
that occurs in the pre-diabetic phase when atherogenesis occurs as opposed to treatment
aimed at reducing the resulting hyperglycemia [357-359] in the diabetic phase only.
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Table 1
Hamster Body Weights
Group/Weeks

Initial Weight

Final Weight

N/10

96.3 ± 3.5

100.8 ± 4 .6

N/20

94.6 ± 5.6

109.0 ± 7 .0 *

L/10

94.7 ± 4 .5

109.7 ± 6 .5 **

L/20

97.8 ± 4 .9

108.0 ± 6 .5

G/10

96.2 ± 3.7

101.3 ± 5 .7

G/20

95.2 ± 5 .0

104.0 ± 7 .7

L+G/10

95.2 ±4.1

101.9 ± 6 .4

L+G/20

96.5 ± 4 .4

107.1 ± 7 .9

M e a n (± S D )

body weight (g).

*Significant increase (p < 0 .0 1 ) over initial

weight. **Significant increase (p < 0 .0 0 1 ) over initial weight and significant
increase (p < 0 .0 5 ) over N /10 final weight.
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Table 3
Significant Differences in Lipids, Glucose, and Insulin at Week 10
TC
(mg/dL)

HDL-C
(mg/dL)

Non-HDLC (mg/dL)

TG
(mg/dL)

TCI HDLC

Glucose
(mg/dL)

Insulin
(ng/ml)

N vs L

***

*

***

ieieic

***

kk

*

N vs G

NS

NS

NS

kkk

NS

kkk

* **

N vs L+G

***

***

***

kkk

***

kkk

* **

G vs L

* * *

*

***

NS

***

kk

NS

L vs L+G

***

* **

***

***

***

kk

* **

G vs L+G

***

***

***

***

***

NS

* **

Groups
Compared

*P < 0.05, ** p < 0.01, *** P < 0.001, NS = not significant. ^ indicates
significant decrease of the second group. All others indicate significant
increase of the second group.
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Table 4
Significant Differences in Lipids, Glucose, and Insulin at Week 20
TC
(mg/dL)

HDL-C
(mg/dL)

Non-HDLC (mg/dL)

TG
(mg/dL)

TCI HDLC

Glucose
(mg/dL)

Insulin
(ng/ml)

N vs L

* **

'k 'k ie

***

*

**

NS

NS

N vs G

NS

**

NS

*

NS

***

NS

N vs L+G

* **

***

***

***

** *

***

***

G vs L

* **

***

***

NS

*

*

*

***

***

***

***

*

***

***

* **

***

***

***

***

NS

***

Groups
Compared

L vs L+G
G vs L+G

P < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant. * indicates
Significant decrease of the second group. All others indicate significant
increase of the second group.
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Figure 1
Experimental Design
1/^ hamsters
receive STZ

60 Male Hamsters

1/2 of STZ and
'A of non-STZ
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10 week timepoint
samples collected from
each group

20 week timepoint
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Figure 2
Normal Hamster Pancreatic Insulin Immuno-reactivity

Sections of normal hamster pancreas at 10 weeks. Purple
chromogen deposition indicates immuno-reactivity with insulin.
200X.

N)

Figure 2 - Normal Hamster Pancreatic Insulin Immuno-reactivity
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Figure 3
Glycemic Hamster Pancreatic Insulin Immuno-reactivity

Sections of glycemic hamster pancreas at 10 weeks. Purple
chromogen deposition indicates immuno-reactivity with insulin.
200X.
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Figure 4
Hamster Aortic Arch Lesion Development

Cross sections of hamster aortic arch at 20 weeks. N
represents non-lipidemic/non-glycemic hamsters, G represents
glycemic hamsters, L represents lipidemic hamsters and L + G
represents lipidemic/glycemic hamsters. 200X.

N)
O

Figure 4 - Hamster Aortic Arch Lesion Development
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Figure 5
Hamster Aortic Arch MDA Immuno-reactivity

Cross sections of hamster aortic arch at 20 weeks. N represents
non-lipidemic/non-glycemic hamsters, G represents glycemic
hamsters, L represents lipidemic hamsters and L + G represents
lipidemic/glycemic hamsters. Red chromogen deposition
indicates immuno-reactivity with MDA. 200X.

Figure 5 - Hamster Aortic Arch MDA Immuno-reactivity
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Figure 6
Hamster Aortic Arch LOX-1 Immuno-reactivity

Cross sections of hamster aortic arch at 20 weeks. N
represents non-lipidemic/non-glycemic hamsters, G represents
glycemic hamsters, L represents lipidemic hamsters and L + G
represents lipidemic/glycemic hamsters. Red chromogen
deposition indicates immuno-reactivity with LOX-1. 200X.
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Figure 6 - Hamster Aortic Arch LOX-1 Immuno-reactivity
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Graph 1
Total Cholesterol
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Graph 2
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b significantly increased over a. c significantly increased
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Graph 3
HDL-C
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Graph 4
TC/HDL-C
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Graph 5
Triglycerides
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Significant increase over G (p< 0.01)
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Graph 10
Correlation between total cholesterol and lipid
hydroperoxides in all hamsters at week 20.
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anesthetics/analgesics.
Approval is granted for a period of three years from the approval date above. Continued approval throughout
the three year period is contingent upon completion of annual reports on the use of animals. At the end of the
three year approval period you may submit a new application and request for extension to continue this project.
Requests for extension must be filed prior to the expiration of the original approval.
Please note: Use of animals in research and instruction is approved contingent upon participation in the UNH
Occupational Health Program for persons handling animals. Participation is mandatory for all principal
investigators and their affiliated personnel, employees of the University and students alike. A Medical History
Questionnaire accompanies this approval; please copy and distribute to all listed project staff who have not
completed this form already. Completed questionnaires should be sent to Dr. Gladi Porsche, UNH Health
Sendees.
If you have any questions, please contact either Van Gould at 862-4629 or Julie Simpson at 862-2003.
thp Institutional Animal Care and Use Committee,
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